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Up to 80% of breast cancer survivors (BCS) treated with chemotherapy report persistent 
cognitive impairment. The precise mechanisms leading to impairment are unclear and there is a lack of 
correspondence between self-reported and objectively measured cognitive deficits due in part to the use of 
non-specific neuropsychological assessments. Further, cognitive impairment in BCS may surface in a 
portion of individuals due to the interaction of several contributing risk factors (e.g. sleep, fatigue, and 
stress) which have not been assessed systematically. Using machine learning, this study combined 
features implicated in chemotherapy-related cognitive impairment (CRCI) from a battery of self-report 
measures, neuropsychological assessments, and three experimental cognitive neuroscience paradigms. 
This approach accurately classified individual BCS at greater risk for experiencing CRCI from healthy 
aging individuals. The most predictive features included a combination of self-report (fatigue, stress, 
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  Breast cancer is a costly medical condition that afflicts nearly 12.4% of American women during 
their lifetime and is the most common form of cancer in women worldwide. With advancements in 
screening and treatment, breast cancer survivorship is on the rise with an average 5-year survival rate of 
89.7% in the United States (Howlader N, Noone AM, Krapcho M, 2016); globally, incidence and survival 
rates can vary substantially (WHO, 2008). With increasing rates of survivorship and relatively stable rates 
of newly diagnosed cases annually, the number of women living with breast cancer faces an upward trend 
(Howlader N, Noone AM, Krapcho M, 2016). Breast cancer treatment, particularly treatment with 
adjuvant (post-surgery) chemotherapy, is associated with persistent cognitive impairment in a substantial 
portion of breast cancer survivors (BCS) (Janelsins et al., 2017a; Joly et al., 2015; Jung et al., 2017; 
Wefel, Vardy, Ahles, & Schagen, 2011). Though highly variable, up to 80% of breast cancer patients 
report some form of cognitive impairment before, during, or after treatment with chemotherapy. Such 
impairment has been shown to negatively impact an individual’s quality of life and interfere with skills of 
daily living (Janelsins, Kesler, Ahles, & Morrow, 2014; Myers, 2013; Wefel, Vardy, et al., 2011). 
Chemotherapy-related cognitive impairment (CRCI) is likely multifaceted (Figure 1); paired with 
an individual’s physical and mental health status, multiple confounds and contributing risk factors (e.g. 
age, genetics, stress, fatigue, & depression) have been shown to alter the magnitude and trajectory of 
CRCI in various cognitive domains (Ahles et al., 2010; Janelsins et al., 2017b; Jenkins et al., 2006; 
Saykin, Ahles, & McDonald, 2003). Cognitive impairment has been linked to cancer pathology and 
treatment with chemotherapy via disruptions in DNA-repair mechanisms, compromised immune 
functioning and stress (Ahles & Hurria, 2018; Ahles & Saykin, 2007; Joerg Dietrich, Han, Yang, Mayer-
Pröschel, & Noble, 2006). Persistent cognitive impairment post-treatment has been associated with   
 
2 
chemotherapeutic toxicity in both human and animal models (Ahles & Saykin, 2007; J. Dietrich, Prust, & 
Kaiser, 2015; Merriman, Von Ah, Miaskowski, & Aouizerat, 2013; Pendergrass, Targum, & Harrison, 
2018).  
Crucially, at present there is no consensus regarding the presence or magnitude of cognitive 
impairment in any one given cognitive domain. Such inconsistencies stem from methodological 
variability and the use of neuropsychological assessments designed to detect broad, non-specific deficits 
in general cognitive functioning. A history of neuropsychology highlights efforts to describe general 
cognitive dysfunction based on properties that can be localized to specific brain regions based on clinical 
presentation in single case studies with major neurological damage (Horowitz et al., 2018; Ruff, 2003). 
These assessments may lack the sensitivity to detect subtle cognitive impairment with any precision in 
clinical samples such as in BCS (Horowitz, Suls, & Treviño, 2018; Silverstein, 2008; Vardy, Wefel, 
Ahles, Tannock, & Schagen, 2008). As highlighted within several recent large-scale meta-analyses, 
impairments in BCS are most commonly found in the cognitive domains of attention, memory, and 
executive functioning, with additional consistent reports of impaired processing speed (Jansen, 
Miaskowski, Dodd, & Dowling, 2007; Jim et al., 2012; Lindner et al., 2014; Ono et al., 2015; Yao, 
Bernstein, & Rich, 2017). Whether the impairment is specific to cancer, cancer treatment, or some 
combination of factors as a function of age, requires further evaluation (Loh et al., 2016; Mandelblatt et 
al., 2013). As highlighted by Ahles & Hurria (2018), current challenges in cancer treatment, CRCI and 
psycho-oncology research revolve around the number of possible determinants (e.g. contributing risk 
factors) implicated in CRCI. Each determinant has the potential to impact the presence, type, severity and 
trajectory of either perceived or objectively measured cognitive impairment in heterogeneous patient and 
non-patient samples (see Figure 1; Ahles & Hurria, 2018).  
  Symptoms of fatigue, sleep disturbances, stress, and depression have all been reported in 
conjunction with cognitive complaints before, during (Hermelink et al., 2015; Scherling, Collins, 
MacKenzie, Bielajew, & Smith, 2011; Wefel, Vidrine, et al., 2011), and after treatment with 





2015; Joly et al., 2015; Vearncombe et al., 2009). As stated above, age may also be a determining factor. 
Increases in life expectancy have resulted in higher proportions of elderly individuals (≥65) diagnosed 
with breast cancer annually. Cognitive decline is a part of normative aging, yet investigations into the 
specific cognitive impairments faced by BCS, particularly those further along on the aging continuum, is 
limited (Edwards et al., 2018; Joly et al., 2015; Lange, Rigal, et al., 2014). Cognitive impairment in BCS 
may thus surface in a portion of individuals due to the interaction of several contributing factors, the 
impact of which has not been assessed systematically.  
  The following introduction [unavoidably and necessarily] traverses issues related to CRCI in BCS 
in greater detail. The intent is to construct a well-formulated argument that advocates the need for a 
comprehensive and systematic approach to the study of CRCI. Below, I first discuss limitations with 
neuropsychological assessments and why such tests may be insufficient for detecting subtle and specific 
cognitive impairment in BCS. I then briefly introduce one of the experimental paradigms selected from 
the cognitive neuroscience literature that have been designed to assess individual differences in specific 
Figure 1. The complexity of CRCI. A schematic detailing the number of potential contributors 






cognitive domains implicated in CRCI. These paradigms are herein referred to specifically as 
experimental cognitive neuroscience paradigms. Next, I discuss several factors most commonly reported 
to contribute to CRCI, including potential mechanisms and risk factors by which chemotherapy may 
affect cognition as relevant to the current study. I highlight and discuss the need for a comprehensive 
modeling approach capable of handling the complexity of CRCI that can distinguish individuals with 
breast cancer from healthy age-matched control participants (HC). Finally, I state the rationale and aims 
of this study before presenting the results and discussion. 
 
Assessment & Cognition in BCS 
Cognitive dysfunction has been assessed across a wide range of cognitive domains in women 
with breast cancer. Cognitive domains assessed include visuospatial ability, verbal learning, memory, 
attention, and executive function. As substantiated by several recent meta-analyses, reports of cognitive 
deficits within these domains vary significantly across studies and assessments (Jim et al., 2012; Lindner 
et al., 2014; Ono et al., 2015; Yao et al., 2017). As highlighted within the introduction, 
neuropsychological assessments measure global or general aspects of cognitive functioning and do not 
differentiate between the multiple component processes involved in a given cognitive domain (Horowitz 
et al., 2018; Nelson & Suls, 2013; Wefel, Vardy, et al., 2011). For example, executive functioning (EF) is 
an umbrella term comprising several complex cognitive control processes. It has been theorized that 
dissociable sub-components of EF include inhibitory and interference control (response inhibition), 
working memory (monitoring and updating) and cognitive flexibility (shifting) (Diamond, 2013; Miyake, 
Emerson, & Friedman, 2000). Inhibitory control processes enable an individual to exhibit effortful control 
over prepotent or automatic responses that are otherwise inappropriate or incorrect in a given context. 
Working memory involves the ability to hold and manipulate information in mind in order to carry out a 
goal. Cognitive flexibility is the ability to actively adapt to changing contextual demands (Miyake et al., 





Deficits in skills required for daily-functioning are commonly self-reported by patients undergoing 
chemotherapy. Examples of such deficits in BCS include forgetting to take one’s medications or to 
schedule a follow-up appointment with a primary care physician (Horowitz et al., 2018). Such impairment 
can negatively affect one’s standard of living or have more serious and perhaps even life-threatening 
consequences, thus it is important studies attempt to understand the specific cognitive processes 
compromised in BCS. 
  EF has been assessed in BCS using a variety of traditional neuropsychological assessments. In 
order to retroactively assess which components of EF are more vulnerable in CRCI, a recent meta-
analysis compared results from 41 independent studies (Yao et al., 2017). Studies were stratified 
according to the component of EF an assessment is purported to measure (inhibitory control: 19 studies; 
cognitive flexibility: 26 studies; working memory: 25 studies). Results of the meta-analysis suggest that 
impairments in EF due to treatment with chemotherapy, while variable, are found more consistently in 
areas of cognitive flexibility and working memory (shifting and updating), but not inhibitory control (Yao 
et al., 2017). However, the greater impairment in cognitive flexibility and working memory was limited to 
cross-sectional studies, thus it is uncertain how stable and reliable these findings are. Yao and colleagues 
(2017) highlight the variable number of assessments used to assess EF and the non-systematic reporting 
of raw versus standardized scores has likely contributed to inconsistencies in the literature regarding 
CRCI and may have contributed to the variable findings in their meta-analysis and lack of evidence for 
deficits in inhibitory control.  
  Returning to the idea of non-specificity, traditional neuropsychological assessments used to 
measure EF simultaneously tap multiple executive and non-executive processes alike. As an example of a 
non-specific assessment of EF, Yao and colleagues discuss the Delis-Kaplan Executive Function System 
(DKEFS) Trail Making Test (Baron, 2004). The Trail Making Test (TMT) is an assessment commonly 
used to measure EF, and more specifically is used as a measure of cognitive flexibility (e.g. shifting). This 





and letters. The particular sequence depends on the level of difficulty for a given condition. In the most 
difficult condition, participants are required to switch or alternate between connecting a number and a 
letter in sequential order (i.e. participants are instructed to draw a line from 1 to A, A to 2, 2 to B and so 
on). In all condition’s participants are prompted to do so as quickly as they can without making mistakes 
(for full task description, see Methods). This task taps multiple executive and non-executive cognitive 
processes (e.g. switching, inhibition, psychomotor speed, visual scanning, sequencing, and motor 
function) which cannot be readily dissociated from one another. McFarland and colleagues (2017) discuss 
an additional example, the digit-span test (Wechsler, 1981) is a task primarily used to index working 
memory that requires participants to remember and recall a sequence of numbers of increasing length. 
This task involves several executive and non-executive processes including short-term memory, verbal 
attention and recall, and motor functioning (McFarland, 2017).  
  As with EF, it is well-established that other high-level cognitive constructs such as attention and 
memory involve multiple sub-processes. For example, attention captures the ability to establish, maintain, 
and flexibly shift attentional focus (Petersen & Posner, 2012; Posner & Boies, 1971). Early memory 
research provides ample evidence that attentional processes are critical for both learning and memory; 
failure to accurately encode or process new information due to deficits in attention limits the acquisition 
and retention of new memories critical for learning (Craik, Naveh-Benjamin, Govoni, & Anderson, 1996; 
Mulligan, 1998). Critically, memory as assessed via traditional neuropsychology tests confounds the sub-
components of memory and attention (Luck & Gold, 2008; Pfeifer et al., 2013). As an example, Nelson 
and Suls (2013) consider a commonly used measure of verbal learning and memory in BCS, the Rey 
Auditory Verbal Learning Test (RAVLT) (Rey, 1941). The RAVLT is a 4-part assessment that requires a 
participant to listen to and remember a series of words. In part 1, a series of 15 words are read aloud by an 
experimenter and the participant must repeat as many words as he/she can remember after the list of 
words is read. This process is repeated over five consecutive trials using the same list of words. In part 2 





by the participant as in part 1. In part 3, after a delay period lasting 20 minutes, the participant is asked to 
recall any words from the first list that he/she can remember. In part 4, a new list of words is read aloud 
by the experimenter, and the participant is asked to decide whether or not a word belonged to the original 
list from part 1. As discussed by Nelson and Suls (2013), though the RAVLT is primarily used as an 
index of general memory ability, multiple component processes of memory (encoding, recognition, and 
retrieval), attention (selective and sustained) and executive functioning are involved (Nelson & Suls, 
2013; Schmidt, 1996). Concerning memory deficits observed in BCS, Horowitz and colleagues (2018) 
suggest that problems with performance on traditional memory assessments commonly used in CRCI 
research may be due to issues with initiating or maintaining attention, rather than memory processes per 
se (Horowitz et al., 2018).  
  Traditional neuropsychological assessments such as the RAVLT rely on the use of single 
summary scores (i.e. one trial, one score) to assess average performance (Casaletto & Heaton, 2017). 
Summaries of global composite scores are impervious to the multiple cognitive operations underlying a 
particular score observed for a given individual. Such tasks, which may be capable of measuring large 
pathological cognitive impairment, are thus perhaps not suitable for detecting subtle and specific changes 
in cognition (Collins, Widmann, & Tasca, 2018; Tales et al., 2012; Wang, Ding, & Kluger, 2014). 
  Experimental cognitive neuroscience paradigms are designed to disentangle sub-components of 
cognitive processes within a given cognitive domain (e.g. attention or executive function) (Barch et al., 
2009; Costa et al., 2017; Horowitz et al., 2018; Silverstein, 2008; Van Der Plas et al., 2017; Wefel, 
Vardy, et al., 2011). Experimental cognitive neuroscience paradigms afford research scientists the ability 
to analyze individual patterns of performance using multiple metrics of accuracy, response time, and 
response time variability measured independently across conditions comprised of many trials with 
varying levels of difficulty (Luck & Gold, 2008). The increased specificity and flexibility of experimental 
paradigms can thus improve upon general neuropsychological assessments to inform studies of CRCI. 





consortium were created with the intent of optimizing and validating several experimental tasks based on 
theoretical and translational work in cognitive neuroscience for use in patient populations (Barch et al., 
2009; Carter et al., 2011). For example, to address methodological issues with neuropsychological 
assessments of memory such as the RAVLT discussed above, the CNTRACs consortium developed the 
Relational and Item Specific Encoding Task (Ragland et al., 2012; see Methods & Materials for a full 
task description). This task is an episodic memory task designed to assess both the encoding and retrieval 
stages of memory for individual items and relational pairs. Participants complete several rounds of testing 
and see a large number of items. During this task, a participant’s performance is constantly monitored 
(accuracy, response time, response time variability) for every item across all conditions (item-encoding, 
relational-encoding, item-retrieval, relational retrieval). This task then, improves upon 
neuropsychological tests that probe episodic memory in its ability to assess distinct contributions of 
different stages of memory, as well as assess the role of attention on performance, and processing speed.  
  The efforts made by the CNTRACs consortium are important for clinical research as they address 
issues inherent to traditional neuropsychological assessments (non-specificity, practice effects, use of 
summary scores, etc.) to develop robust paradigms sensitive to individual variability in performance, and 
permit comparisons between heterogeneous clinical and non-clinical samples (Barch et al., 2009; 
Silverstein, 2008). Improving the detection and measurement of non-pathological cognitive impairment is 
critical for assessing specific cognitive deficits in CRCI (Horowitz et al., 2018; Pendergrass et al., 2018; 
Wefel, Vardy, et al., 2011). 
 
Mechanisms & Contributing Factors of CRCI 
 
Despite studies failing to find statistically significant deficits in general cognitive domains, non-
central nervous system cancer pathology (e.g. breast, lung, etc.) and various chemotherapeutic regimens 
have been shown to coincide with cognitive deficits before, during and after treatment in a portion of 





theoretical and empirical support for biologically-based mechanisms and pathways by which cancer 
pathology and treatment-related toxicities can contribute to cognitive dysfunction, particularly in aging 
samples (Mandelblatt et al., 2013; Merriman et al., 2013; Wefel, Kesler, Noll, & Schagen, 2015).  
Post-Treatment Cognitive Impairment. Chemotherapy agents comprise several classes but 
can be broadly classified into anthracycline and non-anthracycline-based regimens. Anthracycline agents 
are anti-tumor antibiotics, are the most common, and potentially most toxic. Anthracycline regimens are a 
combination of anthracycline-specific and non-anthracycline-based agents. Chemotherapy agents work by 
damaging DNA directly, targeting DNA repair and maintenance processes (e.g. cleavage), or by 
interrupting the cell-cycle at various stages leading to apoptosis (cell death) and neurodegeneration 
(Pendergrass et al., 2018; Winocur et al., 2018). The cytotoxic effects of chemotherapy agents differ 
depending on the class of drug an individual is prescribed. Certain treatment regimens or drug 
combinations may contribute to CRCI more than others (e.g. 5-fluorouracil, doxorubicin, and 
cyclophosphamide (Wefel et al., 2015). The degree to which cognitive impairments detected in BCS are 
dose-dependent remains uncertain (Cheung, Chui, & Chan, 2012; Collins, Mackenzie, Tasca, Scherling, 
& Smith, 2013; Fardell, Vardy, Logge, & Johnston, 2010; Kreukels et al., 2006; Mehlsen, Pedersen, 
Jensen, & Zachariae, 2009; Mehnert et al., 2007).  
  Recent work has found differential cognitive deficits and neural alterations in women treated with 
anthracycline and non-anthracycline based chemotherapy regimens (Kesler & Blayney, 2016). Cellular 
level toxicities resulting in cognitive dysfunction have been shown to contribute to the development of 
dementia in some BCS patients. Whether or not a BCS develops dementia appears to be contingent on age 
at the time of diagnosis and the expression of certain genetic risk factors involved in the regulation of 
neuromodulators which promote healthy brain functioning and cognition, particularly within the realms of 
attention and memory (Ahles & Hurria, 2018; Heck, Albert, Franco, & Gorin, 2008; Wefel et al., 2015). 
At the neural level, research has found general problems with learning and memory involving structural 





chemotherapy. The precise mechanisms leading to such impairment have for the most part remained 
elusive. Alterations in behavior and cognition have been shown to arise from cancer tumor pathology 
itself, chemotherapy, chronic inflammation (stress-induced), or treatment-induced hormonal imbalances 
(Golan, Lev, Hallak, Sorokin, & Huleihel, 2005; Kovalchuk & Kolb, 2017; Seigers & Fardell, 2011). A 
majority of findings have focused on decreased neurogenesis and cell proliferation in the hippocampus, a 
region critical for learning and memory (Kaiser, Bledowski, & Dietrich, 2014b). However, widespread 
changes in brain structure (volumetric reductions in both white and grey matter) and function have been 
observed in human and animal models after treatment with chemotherapy (Inagaki et al., 2007; Shelli R. 
Kesler & Blayney, 2016). Global changes in brain structure and function further underscore the need for 
cognitive paradigms that are capable of addressing the variability and uncertainty regarding the specific 
components of cognition most effected due to treatment with chemotherapy.  
  Physical manifestations of chemotherapeutic toxicities include hair and weight loss, nausea, and 
bowel-dysfunction. Side-effects resulting from chemotherapy treatment can negatively impact an 
individual’s overall health and well-being, which in turn can lead to a general decrease in cognitive 
functioning. Additionally, chemotherapy itself may accelerate the aging process (Brouwers et al., 2016; 
Shelli R. Kesler, Rao, Ray, & Rao, 2017; Mandelblatt et al., 2016), a hypothesis supported by several 
lines of research at the molecular and systems-biology level (Kovalchuk & Kolb, 2017; Sanoff et al., 
2014; Seigers & Fardell, 2011). Considering mechanisms by which chemotherapeutic agents can 
influence cognitive impairment can help further pinpoint potential areas of cognitive dysfunction at the 
neurobiological level (Ahles & Saykin, 2007; Janelsins et al., 2014; Lacourt & Heijnen, 2017; Saykin et 
al., 2003; Winocur et al., 2018). 
  Clinical & Psychosocial Determinants. Breast cancer risk is reported to increase with age and 
previous studies have reported worse cognitive impairment and decline with increasing age in BCS 
(Ahles et al., 2010). Compared to younger cohorts, elderly patients (>65) may present with unrelated 





2014; Lange, Rigal, et al., 2014). How an individual may respond to treatment with chemotherapy, and 
the extent to which one can cope with adverse side-effects and symptoms of cognitive impairment is, 
therefore, further complicated by issues unique to aging populations. Aging individuals experience 
normative, yet variable degrees of cognitive decline (Cabeza, Nyberg, & Park, 2009; Campbell, Hasher, 
& Thomas, 2010; Salthouse, 2017), but when and how this decline develops is still a matter of debate 
(Salthouse, 2009). Indeed, in addition to normative declines in processing speed, non-pathological age-
related cognitive impairment is known to occur across both general and specific cognitive domains, such 
as memory and task-switching ability, respectively. In the absence of cancer or cancer treatment, 
normative aging is associated with declines in various forms of higher-order cognition implicated in 
CRCI such as memory, attention and executive function (Lange, Rigal, et al., 2014; Ono et al., 2015; 
Salthouse, 2009). Normative age-related cognitive decline may negatively interact with chemotherapy 
treatment to confer an increased susceptibility toward experiencing CRCI and commonly reported 
secondary effects, most notably depression and fatigue (Lange, Giffard, et al., 2014; Maccormick, 2006; 
Vearncombe et al., 2009).  
  Symptoms of fatigue, sleep disturbances, stress, and depression have all been reported in 
conjunction with cognitive complaints before (Hermelink et al., 2015; Scherling et al., 2011), during 
(Bower et al., 2011; Ganz, 2012), and after (Ahles et al., 2012; Ho et al., 2015; Joly et al., 2015; 
Vearncombe et al., 2009) treatment with chemotherapy in a subset of breast cancer survivors. 
Independent of cancer or cancer treatment, fatigue, sleep, stress and altered mood states such as 
depression (Hammar & Ardal, 2009; Lam, Kennedy, Mclntyre, & Khullar, 2014) are associated with 
cognitive deficits. Critically, such factors are often co-expressed and have been shown to form diagnostic 
clusters or networks of causally linked variables that present to differing degrees across individuals and 
neuropsychiatric and neurological disorders (Cramer, Waldorp, Van Der Maas, & Borsboom, 2010; 
Kossakowski et al., 2016). Following this perspective, a handful of studies have modeled the statistical 





Ho et al., 2015). While these particular studies did not include any measure of cognitive function, they 
provide evidence that such factors are indeed co-expressed differently across individuals with and without 
breast cancer. Further, this research indicates that clustering (e.g. grouping associated factors) may be one 
approach for identifying individual risk factors in BCS that can then be associated with cognitive 
impairment. To date, one study has followed up on this line of evidence and employed clustering to 
examine how risk factors implicated in CRCI can be linked to cognitive impairment. Xu et al. (2018) 
computed an average composite score from a battery of traditional neuropsychological assessments to 
show that relatively poorer cognitive function in BCS before, during, and shortly after treatment with 
chemotherapy was directly related to the quality of sleep. Fatigue itself was indirectly linked to poorer 
cognitive performance through its association with overall sleep quality.  
  Currently, there is no consensus as to what risk factors contribute to CRCI. This discrepancy may 
arise due to the characteristics of a given sample under investigation or methodological and analytical 
variability. Age, genetic predisposition, and resilience to stress amongst other factors interact to confer 
risk for experiencing cognitive dysfunction. Clearly more work is needed that considers the complex and 
high-dimensional interaction between these and potential contributing risk factors implicated in CRCI. In 
theory, CRCI may arise from the interaction of demographic, psychosocial, and cognitive factors, no 
study has systematically addressed this issue. 
 
Modeling & Prediction 
 
The complexity of CRCI and associated mechanisms, paired with small sample sizes and poorly 
matched comparison groups, has contributed greatly to inconsistencies evident throughout the literature 
regarding the nature of CRCI (Ahles et al., 2012; Janelsins et al., 2014; Wefel, Vardy, et al., 2011). 
Researchers and clinicians can take advantage of a set of statistical approaches that are capable of 
discovering intricate patterns or relationships between variables in multidimensional datasets which can 





Machine learning tools are predictive modeling techniques designed to deal with high-dimensional and 
diverse datasets (Altman & Krzywinski, 2017; Breiman, 2001; Denisko & Hoffman, 2018). 
  Applications of Machine Learning. From genomic sequencing to artificial intelligence and 
image recognition, machine learning tools provide a robust framework to tackle complex issues. Machine 
learning tools are most appropriate in instances when the underlying cause or set of causal factors for a 
given disease, disorder or impairment is unknown, or may likely result from the interaction of multiple 
contributing risk factors (Bzdok & Meyer-Lindenberg, 2018; Dwyer, Falkai, & Koutsouleris, 2018; 
Iniesta, Stahl, & McGuffin, 2016). Machine learning tools are commonly used in precision or 
personalized medicine in order to help medical practitioners develop individualized drug-based treatment 
plans and has been shown to improve diagnostic, prognostic and treatment-related outcomes (Bzdok & 
Meyer-Lindenberg, 2018; Dwyer et al., 2018; Iniesta et al., 2016). Specifically, machine learning has 
been used to predict how individuals with various types of cancer will respond to commonly prescribed 
chemotherapeutic regimens based on the genetic profile of a cancerous tumor before and after treatment 
with high accuracy (>80%) (Huang et al., 2018; Zhang, Wang, & Xu, 2006). Additionally, machine 
learning is now commonplace in cancer drug development where the goal is prediction and subsequent 
reduction of drug-induced toxicities (Wu & Wang, 2018). As discussed in several reviews (Bzdok & 
Meyer-Lindenberg, 2018; Dwyer et al., 2018; Iniesta et al., 2016), machine learning tools are being used 
to aid in the development of targeted pharmacological therapies for individuals with treatment-resistant 
depression (Grisanzio et al., 2018; Kautzky et al., 2017), to predict an individual’s risk of developing 
Alzheimer’s dementia (Geifman, Kennedy, Schneider, Buchan, & Brinton, 2018; Lebedev et al., 2014) or 
to aid in early detection of Parkinson’s Disease (Faghri et al., 2018; Prashanth, Dutta Roy, Mandal, & 
Ghosh, 2016). Machine learning is also increasingly being used as a data-driven alternative to the 
Diagnostic and Statistical Manual of Mental Disorders to help identify data-driven subgroups of 
individuals with neurodevelopmental disorders such as Attention Hyperactive Deficit Disorder and 





Feczko et al., 2018).  
  Machine Learning & CRCI in BCS. To date, few studies have used machine learning to study 
CRCI. In 2013, a study by Kesler and colleagues used functional magnetic resonance imaging (fMRI), IQ 
testing, a battery of traditional neuropsychological assessments and self-report questionnaires to compare 
BCS who had received treatment with chemotherapy (N=30), with BCS who did not receive treatment 
with chemotherapy (N=27) and healthy women with no history of breast cancer or treatment with 
chemotherapy (N=24). fMRI was used to measure intrinsic (task-free) coordinated brain activity between 
19 discrete brain regions belonging to the default mode network (DMN). The DMN is a well-established 
collection of brain regions that communicate with one another during mental operations that are internally 
focused such as autobiographical memory, socioemotional processing and the monitoring of internal 
physiological states (Buckner, Andrews-Hanna, & Schacter, 2008; Raichle & Snyder, 2007). The DMN 
has consistently been shown to be vulnerable to various disease processes, stressful and traumatic 
experiences, pharmacological intervention and aging (Broyd et al., 2009; Buckner et al., 2008). Kesler 
and colleagues specifically targeted the DMN based on prior research linking alterations in DMN 
functioning to cognitive impairment in BCS treated with chemotherapy (Dumas et al., 2013). In this 
seminal study, machine learning was used to accurately distinguish (e.g. classify) BCS treated with 
chemotherapy from BCS not receiving chemotherapy and healthy age-matched control participants with 
no history of cancer based on DMN connectivity alone (S. R. Kesler et al., 2013). The authors report a 
positive correlation between subjective memory impairment and classification accuracy, but no 
differences were found between groups on any of the neuropsychological assessments using an analysis 
of variance. The authors suggest that the lack of group mean differences are likely due to the substantial 
amount of heterogeneity in BCS populations and limitations with traditional statistical tests that average 
group performance.  
  In a follow-up study, Kesler et al. (2017) built on this work by combining patient health 





theory to predict long-term cognitive impairment in a sample of 31 BCS ages 34-65 using machine 
learning. Graph theory is a set of mathematical tools used to describe the brain as a network of 
interconnected regions. Here, the authors calculated regional clustering coefficients (e.g. clustered 
connectivity), a mathematical formula from graph theory which quantifies how well a brain region is 
connected to other regions in close proximity. This organizational property of brain networks is said to 
index the efficiency of information transfer in brain networks important for cognitive functioning 
(Rubinov & Sporns, 2010) and has been shown to be compromised in BCS after treatment with 
chemotherapy (Bruno, Hosseini, & Kesler, 2012; Hosseini, Koovakkattu, & Kesler, 2012; Shelli R. 
Kesler, Watson, & Blayney, 2015). In this study, BCS completed a single fMRI scan prior to treatment 
and cognition was assessed before, shortly after (1 month), and 1-year post-treatment with chemotherapy. 
Additionally, a group of 43 age-matched healthy women with no history of cancer or cancer treatment 
was used to obtain normative scores on neuropsychological assessments. Scores from each 
neuropsychological assessment obtained from BCS were standardized using the mean and standard 
deviation of the reference healthy control group. BCS having scores greater than 1 or 2 standard 
deviations below the reference group were considered impaired.  
  Specifically, Kesler and colleagues (2017) used a model-building approach to test three separate 
statistical learning models in their respective ability to predict CRCI. One model included patient 
demographic and medical data (model 1), a second model (model 2) combined model 1 data with 
clustering coefficients from 3 specific brain regions belonging to the DMN identified in a previous study 
(Shelli R. Kesler, Rao, Blayney, et al., 2017; right middle orbitofrontal gyrus, right inferior parietal 
lobule, and right mesial superior frontal gyrus), and a third [full] model (model 3) combined model 1 and 
clustering coefficients from 80 anatomically-defined regions spanning the entire brain. From these models 
features that contributed most to model classification accuracy were used to predict cognitive decline in 
BCS 1-year post-treatment. All models were able to accurately classify impaired vs. unimpaired BCS 





specificity = 0.75; model 3: 100% accuracy, sensitivity = 1.0, specificity = 1.0). As hypothesized by the 
authors, a model using imaging data alone (model 2), or in combination with demographic and medical 
information (model 3; best performance) provided greater classification accuracy than the model 
comprised exclusively of non-imaging data (model 1). Models 2 & 3 were less accurate and not 
significantly different from one another (Shelli R. Kesler, Rao, Blayney, et al., 2017).  
  Implications. The aforementioned studies illustrate the potential for machine learning to unravel 
the complexity of CRCI. In the Kesler et al. (2012, 2017) studies, the authors were able to accurately 
classify BCS as impaired versus unimpaired, and predict future cognitive decline using several features 
from different modalities. Machine learning studies of this type permit discovery and represent an 
important step forward in CRCI research. However, it remains unclear how these findings relate to 
cognitive dysfunction. In these studies, cognition was either indirectly inferred via self-report and not 
explicitly modelled, or was assessed with non-specific neuropsychological assessments which were used 
to create a sample-specific cognitive impairment score (RAVLT, TMT; see Assessment & Cognition in 
BCS for specific discussion of these measures). As Kesler and colleagues (2017) note, the assessments 
and diagnostic criteria were chosen primarily for harmonizing studies of cancer and cognition and future  
studies should thus focus on improving cognitive assessments to identify the specific components of 
cognition compromised in CRCI. In combination with machine learning, the development of measures 
that can accurately and mechanistically explain CRCI can be used to better inform future diagnostic 
criteria and identify individuals who may be at greater risk for experiencing great cognitive impairment 
and decline (Wefel, Vardy, et al., 2011). A common machine learning tool is the random forest algorithm 
(used in Kesler et al., 2017; also see the studies highlighted above in the subsection entitled Applications 
of Machine Learning).  
  An overview of random forest classification. A random forest is a collection of decision trees. 
Decision trees are appropriately named for their tree-like appearance and are used to categorize or group 





people, music, movies, food and so on. In the case of people, descriptive features could include age, 
gender, weight, heart rate, personality traits, likes and dislikes. Classes or labels might represent 
dichotomous categories such as sick or healthy, or BCS or HC. As a machine learning tool, a decision tree 
is tasked with learning a set of rules that best divides a dataset into its respective classes. This set of rules 
can later be used to make predictions as to which class a new unfamiliar object might be classified.  
  Within a given decision tree (see Figure 2), 
a dataset is split into branches (connections) and 
nodes (features) in a hierarchical manner. Starting 
at the root node (top of a tree), the data is split on a 
feature that best differentiates a set of items or 
observations. From the top of the tree, branches 
extend downward to form connections with 
internal nodes that contain other features that next 
best differentiate a set of items. This process 
occurs until no more splits are possible and a 
decision is reached at a final terminal node. To 
grasp how a decision tree works in practice, 
consider how a person may decide to go outside 
and exercise or stay home and read. The decision 
to go outside and exercise or not can be based on 
features that describe the weather, the person’s 
current mood state, health status, love of reading 
and so on. In this example, the most reasonable 
choice to exercise or not depends on whether or 
not the person is feeling ill. So, starting at the root node with health status, the decision process begins by 
Figure 2. Simplified decision tree. Example 
depicts the basic components of a decision 
tree. Starting from the top of a tree, the root 
node represents the feature that best splits a 
set of observations into their respective 
classes (HC, BCS). From the root node, a set 
of split observations is sent down their 
respective branch to the next decision point 
at an indicator node. This process is repeated 
until no more splits are possible and a 
decision is reached at a terminal node. At 
each terminal node, a final decision is made 





asking if the person sick? If not, is it raining? If not, is it too windy? If it is not too windy, does the person 
love reading too much? If not, go exercise! In this example, the final decision can only be one of two 
choices that are known a priori: go outside or stay home and read and is thus considered a form of 
supervised machine learning.  
  In this study, the goal was to develop classification models that are capable of distinguishing 
breast cancer survivors from healthy control participants using a combination of clinical, demographic, 
psychosocial, and cognitive measures. Here, we can consider features such as fatigue and depression, as 
well as performance on an attention task (see Figure 2; example and graphics for illustration purposes 
only). As depicted in figure 2, the best split occurs at the root node on the depression. Individuals 
experiencing less depression move down the tree following a branch to the left, while individuals 
experiencing higher depression move down the tree by following the branch to the right. The branches 
extend downward to an internal node. Each internal node contains a feature, such as fatigue and attention 
in this example, that provides the next best split of the data into their respective classes. When the data 
can no longer be split, a final decision is reached at a terminal node. In the case of fatigue, no further 
splits are possible, and individuals who are (1) lower on depression and (2) higher on fatigue are 
classified as BCS. For attention, a portion of higher-performing healthy individuals can be classified 
immediately, however, there is a degree of overlap for those performing at a lower level. The remaining 
individuals must be split again until a decision can be reached. 
  Decision trees can learn from data by revealing values for a given feature that best splits a set of 
observations into their respective class. The learned values at each split in the tree are then used to derive 
the set of rules that guide future predictions. Most decision processes are not as simple as in the example 
provided above. Often, classification problems involve a large number of features that can vary greatly 
across items, individuals, and groups. Further, features may interact with one another in unexpected ways. 
For example, individual performance may vary widely between a set of participants on a battery of 





assessments that tap a particular cognitive domain. Further, the variation may be linked to several 
confounding factors such as age, IQ, levels of stress and/or fatigue. This variation cannot be accounted for 
using a single decision tree with a single set of rules, or even many different trees using the same set of 
rules. To circumvent this issue, the random forest combines the predictive power of many decision trees. 
Thus, the random forest is known as an ensemble method. Each decision tree is constructed using a 
different, randomly selected subset of observations and features, a process known as bootstrapping. The 
random forest uses the bootstrapped datasets to build and optimize a set of decision trees. This process 
helps to ensure that a set of decision trees are not correlated with one another or overly biased towards a 
specific item or feature within a dataset, thus preventing overfitting or over-modeling of a subset of data. 
The set of unbiased trees is then combined or aggregated (bootstrap aggregating; also known as bagging) 
resulting in an unbiased model. The most predictive features are those which contribute the greatest to 
classification on average across the set of bootstrapped decision trees. The random forest can be used in 
conjunction with cross-validation, a set of partitioning schemes used to split a dataset into multiple 
training and test sets. Although, the random forest estimates misclassification internally (out-of-bag-
error), external cross-validation can be used to assess generalizability - the ability for a random forest 
model to correctly classify new and unseen data not used to build or optimize an ensemble of decision 
trees. As in Figure 3, a common cross-validation technique is k-fold cross-validation whereby a dataset is 
randomly partitioned in k equal groups. On each fold, one of the partitioned k samples is set aside and 
used exclusively for testing the accuracy or generalizability of a random forest model, all remaining k 
samples are then used as training data and submitted to the random forest.  
  Random forest ensemble methods have been shown to outperform various classification 
algorithms on datasets varying in sample size and dimensionality (Briand, Ducharme, Parache, & Mercat-
Rommens, 2009).  Importantly, with a limited sample size and a moderate number of features, the random 
forest application appears to be one of the most stable machine learning algorithms (Briand et al., 2009). 





best distinguishes BCS from HC. 
Figure 3. Random forest model. Prior to constructing the random forest, a dataset is partitioned into 
training and test sets. In this example, K-fold cross-validation is used whereby the dataset is randomly 
partitioned in K equal groups. On each fold, one of the partitioned K samples is set aside and used 
exclusively for testing the accuracy of a random forest model. The random forest model is constructed by 
building a series of N decision trees using a bootstrapped training set. Here, for each of N bootstrapped 
decision trees, two-thirds of the available training data is randomly selected to build the tree. The 
remaining one-third of data is used to optimize a given tree by reducing the overall classification error. 
The unexplained error for each tree is known as the out-of-bagged error. After optimization, all N 
decision trees are combined and a final set of rules are used to classify new unseen observations from the 
external cross-validation set. The average performance is taken over the set of K models.  
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RATIONALE & APPROACH 
A central theme of the current work, is that previous research, limited by methodological and 
analytical choices, has not addressed the complexity of CRCI. Such choices have flooded the literature 
with inconsistencies regarding the precise nature of CRCI (Argyriou, Assimakopoulos, Iconomou, 
Giannakopoulou, & Kalofonos, 2011; Ganz, 2012; O’Farrell, MacKenzie, & Collins, 2013; Shilling, 
Jenkins, & Trapala, 2006). Guided by previous empirical & theoretical research, this study aims to 
address the ubiquitous inconsistencies prevalent amongst prior studies assessing CRCI in women BCS. 
To do so, a rigorous hypothesis-driven study design was combined with robust exploratory data-driven 
analytics to model the complex relationship between cancer, chemotherapy, and cognition. A combination 
of performance metrics from experimental cognitive paradigms, commonly administered 
neuropsychological assessments, self-report measures, and demographic information (see Supplemental 
Table 1 for a full list of features labels and individual descriptions) was used to distinguish BCS women 
from healthy control participants. This approach is in accordance with recommendations set forth by the 
International Cancer and Cognition Task Force (Wefel, Vardy, et al., 2011). 
  Leveraging experimental cognitive neuroscience paradigms permits the assessment of subtle 
deficits in specific components of cognition in BCS having received chemotherapy. In contrast, the use of 
commonly recommended neuropsychological assessments enables direct comparisons to previous 
research that has assessed general cognitive deficits in BCS.  
Further, some studies have found group mean differences using traditional neuropsychological 
assessments, and on average the tests require less time to administer. By assessing novel experimental 
cognitive paradigms and traditional neuropsychological experiments in parallel, it is possible to identify a 
combination of performance metrics that best capture cognitive impairment in BCS. Critically, two of the
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experimental cognitive neuroscience tasks administered in this study have been developed for use in 
clinical populations. Further, each experimental cognitive neuroscience paradigm selected for use the 
current study was designed to be (1) resistant to repeated-testing/practice effects, (2) have high test-retest 
reliability, and (3) permit measurement of trial-by-trial variations in performance (accuracy and response 
time). Repeated-testing/practice effects occur when the baseline measurement and longitudinal 
assessment of cognitive functioning is obscured by familiarity or overexposure through repeated 
administration (Naglieri et al., 2004). Though not limited to the study of CRCI, practice effects have been 
implicated as one potential source which has contributed to inconsistent reporting of cognitive 
impairment and decline in BCS (Andreotti et al., 2016; Cerulla et al., 2018). Each task was additionally 
selected based on an ability to assess and quantify specific sub-components of cognitive domains 
specifically implicated in CRCI research. However, these experimental paradigms have not been 
extensively tested and validated in older adults (≥ 65 years of age) or administered to BCS prior to this 
study. It was therefore of utmost importance to validate the use of these tasks in the current sample and 
assess the feasibility of administering a comprehensive battery of assessments to BCS. 
  The combination of assessments administered in this study may provide additional information or 
insight into the cognitive deficits experienced by BCS. However, direct comparisons (subjective, 
statistical or otherwise) between standardized and experimental tasks warrants caution (Silverstein, 2008).  
Experimental cognitive neuroscience tasks differ from traditional assessments in a number of ways and 
permit researchers to isolate and assess specific sub-components of cognition. This limits direct statistical 
comparison to measures optimized for assessing general cognitive deficits, or for use in a specific 
population where impairments can be large and diffuse. Specifically, experimental tasks focus on 
optimizing specific psychometric properties across diverse individuals within clinical and non-clinical 
populations alike. The discriminating power, reliability, and validity of an assessment each respectively 
help to ensure a measure (1) is not susceptible to floor or ceiling effects and nor restricted to a limited 
range of scores, (2) is reliable in the sense that scores observed are consistent across repeated-testing 





functions and abilities it is purported to measure (Cooper, Gonthier, Barch, & Braver, 2017). 
Experimental tasks often contain several conditions each with a large number of trials and may differ in 
their level of difficulty and administration time. The properties of an experimental task can be modified 
for a particular study or population. Traditional neuropsychological tasks, many of which only provide a 
single version, are singe-trial designs that often rely on single-summary score metrics to assess 
performance. Finally, while experimental tasks may hold several advantages over traditional 
neuropsychological assessments for assessing specific aspects of cognition, it remains to be determined 
how performance measures on these tasks correlate with age and levels of fatigue, stress, and other 
potential contributing risk factors that have been consistently implicated in CRCI. Thus, this study 
assessed how performance on experimental cognitive paradigms corresponded to performance on 
traditional neuropsychological assessments, self-perceived cognitive functioning, and self-reported levels 
of contributing risk factors (e.g. sleep, fatigue, depression, etc.) consistently implicated in CRCI. Further, 
this study sought to identify the extent to which general and specific impairments in cognitive function 
are impaired in BCS and the degree to which deficits in general and specific cognitive components 
distinguish BCS from HC. Using machine learning, the primary aim of the study was to determine if BCS 
could be accurately distinguished from HC, and whether or not cognitive neuroscience paradigms provide 
greater predictive value than neuropsychological assessments. I hypothesized that a random forest model 
trained on a combined feature set would accurately classify BCS from HC. Based on the most consistent 
findings from previous research, I expected that classification accuracy and overall model performance 
would rely most heavily on self-reported measures of cognitive impairment and clinical variables 
including sleep, fatigue and mood, as well as specific metrics assessing relational memory encoding, and 
both sustained and selective attention. It was further predicted that metrics assessing cognitive variability 
on attention and executive function measures, particularly response times, during trials from experimental 
cognitive neuroscience tasks would aid in the accurate classification of BCS from HC.
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METHODS & MATERIALS 
 
Participants. The current sample comprised 40 women ages 30-75 (Table 1). 20 women with 
primary, early-stage (I-IIIA) breast cancer who have completed chemotherapy within 1-12 months of their 
scheduled visit date, and 20 healthy female control participants with no history of cancer who have never 
experienced treatment with chemotherapy were recruited. Groups were matched on age, ethnicity, 
socioeconomic status and IQ. All participants were required to be proficient in English, have normal color 
vision, and have no history of neurologic or psychiatric disorders with the exception of anxiety and 
depression. Anxiety and depression are common contributing risk factors for CRCI and are thus not 
considered exclusionary criteria.  
  Treatment Information. All cancer patients completed adjuvant chemotherapy either with or 
without concomitant endocrine therapy (tamoxifen or aromatase inhibitors). Participants were exposed to 
one of two commonly-used regimens: 1) 12 weeks: 4 cycles docetaxel and cyclophosphamide every 3 
weeks; 2) 16 or 20 weeks: 4 cycles doxorubicin and cyclophosphamide every 2 weeks, followed by 4 
cycles of paclitaxel given every 2 weeks or weekly at 12 cycles. Cancer stage and treatment plans were 
confirmed via electronic medical records in compliance with all Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) regulations and provided participant consent. 
 
Overall Procedure 
Participants completed a battery of questionnaires, IQ tests, neuropsychological assessments and 
experimental cognitive paradigms during a single 3-hour session. Individual assessments are described in 
detail below. For all participants, the first portion of a visit consisted of providing written informed 
consent and filling out demographic and health-related questionnaires on an iPad. Following completion  
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of the questionnaires, participants completed either a series of traditional neuropsychological assessments 
or experimental cognitive neuroscience paradigms. The order was counterbalanced between sessions. The 
administration order of individual tests was randomized as well to control for fatigue, test difficulty, and 
trial order effects.  
Questionnaires. Questionnaires included questions about demographics and health history, 
subjective cognitive functioning, sleep quality, physical and mental fatigue, stress, anxiety and depression 
and other quality of life-related factors that have all been implicated in CRCI. 
  Demographics and Health History: This questionnaire asks about the participant’s demographic 
characteristics (e.g. age, weight, education, employment) and health history including current non-cancer 
related medications.  
  The Broadbent Cognitive Failure Questionnaire (CFQ): This 25-item questionnaire asks about 
the participant’s subjective cognitive functioning in everyday life (Broadbent, Cooper, FitzGerald, & 
Parkes, 1982). Using a 5-point Likert scale (0 never; 1 very rarely; 2 occasionally; 3 quite often; 4 very 
often), participants rated themselves on a series of questions assessing absent-mindedness during routine 
daily activities. A total score was calculated (0-100) by summing all item responses. Higher numbers 
indicate greater overall cognitive impairment. Three subscales were computed by summing specific items 
to measure forgetfulness, distractibility and false triggering. This questionnaire can be administered to 
both healthy control participants and patients. The CFQ is one of the most commonly administered self -
report questionnaires assessing cognitive functioning (Cheung, Tan, & Chan, 2012).  
Beck Depression Inventory (BDI): This 21-item questionnaire assesses participant attitudes and 
characteristics on items related to symptoms of depression such as loneliness, hopelessness, fatigue and 
mood. Items are summed resulting in an overall score used to indicate symptom severity (Beck, Ward, 




  BCS (N = 20) HC (N = 20) t/x2 p 
 Age 53.05 (9.89) 49.65 (13.82) -0.895 .376 
 Weight 171.75 (52.82) 162.15 (38.64) -0.826 .414 
 Race/Ethnicity   3.949 .557 
 White/Non-Hispanic 10 14   
 Hispanic 1 1   
 Black/African-American 3 1   
 American Indian 1 2   
 Asian 1 1   
 Multiple Races/Other 3 1   
 Native Hawaiian 1 0   
 Education   1.834 .934 
 High School 1 1   
 Some College 1 1   
 Associate Degree 1 1   
 Four-Year Degree 5 6   
 Master’s Degree 12 10   
 Doctoral Degree 0 1   
Patient Characteristics  
 Treatment ddAC ddAC+PAC PAC  
  9 10 1  
 Time Since Treatment 1-3 4-6 7-9 10-12 
  8 5 4 3 
 Tumor Grade Grade 1 Grade 2 Grade 3  
  4 12 4  
 Receptor Type (+/+/-) (+/-/-) (-/-/-)  
  15 2 3  
Table 1. Sample Characteristics. Breakdown of demographic variables for all participants included in 
the current study, as well as treatment information for breast cancer survivors. ddAC = Dose-Dense 
Adjuvant Doxorubicin and Cyclophosphamide; ddAC+PAC = Dose-Dense Adjuvant Doxorubicin and 
Cyclophosphamide Plus Paclitaxel; PAC = Paclitaxel 
 
  Depression and associated symptoms are commonly reported in BCS and have been linked to 
cognitive impairment. The BDI is a well-validated and reliable measure of depression that has been used 
in prior studies assessing CRCI.  
  Multidimensional Fatigue Symptom Inventory Short Form (MFS): This 30-item self-report 
questionnaire assesses fatigue via several subscales including general fatigue, physical fatigue, emotional 
fatigue, mental fatigue, and vigor (Stein, Martin, Hann, & Jacobsen, 1998). Participants rated themselves 
using a 5-point Likert scale (0 not at all; 1 a little; 2 moderately; 3 quite a bit; 4 extremely) to indicate 
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how relaxed, weak, sluggish or tired they feel. Feelings of fatigue are consistently reported by BCS after 
receiving chemotherapy and can directly impact cognitive functioning (Ganz, 2012; Hurria, Somlo, & 
Ahles, 2007). 
  Pittsburgh Sleep Quality Index (PSQ): This 9-item questionnaire assesses a participant’s overall 
quality of sleep and patterns of sleep disturbance (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). 
Participants rated themselves on a scale from 0-3 with higher scores indicating poorer sleep. Seven 
subscales assess subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleep medication, and daytime dysfunction over the last month. Poor sleep is linked 
to worse cognitive functioning in clinical and non-clinical samples alike and has been shown to co-occur 
with fatigue and depression in BCS (Henry et al., 2018; Xu et al., 2018).  
  Perceived Stress Scale (PSS): This 10-item questionnaire measures a participant’s perceived 
level of stress during daily-life events (Cohen, Kamarck, & Mermelstein, 1983). Participants indicated 
how often they feel stressed due to unpredictable, uncontrollable, or overwhelmingly difficult life events 
using a 5-point Likert scale (0 never; 1 almost never; 2 sometimes; 3 fairly often; 4 very often) to indicate 
how relaxed, weak, sluggish or tired they feel. Increased feelings of physical and mental stress which can 
contribute to cognitive impairment are experienced by BCS after receiving an initial cancer diagnosis and 
upon completing chemotherapy treatment (Evenden, 2013).  
  36-Item Short-Form Health Survey (SF): This 36-item questionnaire assesses general quality-
of-life factors that may or may not interrupt daily activities occurring within 4 weeks of assessment (Ware 
& Sherbourne, 1992). Items from this assessment can be combined to form subscales assessing physical 
functioning, energy level and fatigue, emotional well-being, social functioning, pain, and general health. 
This form is used in conjunction with the CFQ to assess acute changes in daily functioning.  
  Functional Assessment of Cancer Therapy (cancer patients only): This 27-item questionnaire 
assesses the impacts of cancer therapy in four domains including physical, social/family, emotional, and 
functional/cognitive-related outcomes (Yellen, Cella, Webster, Blendowski, & Kaplan, 1997). Subscales 
were summed to derive a total score with higher scores indicating greater overall well-being. Using a 5-
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point Likert scale (0 not at all; 1 a little; 2 some; 3 a lot; 4 very much), participants rated how their overall 
level of health after receiving treatment with chemotherapy. This assessment can help isolate treatment-
specific factors affecting self-perceived physical, mental, social and emotional health occurring over the 
past 7 days since the time of assessment.  
  Debriefing Questionnaires: These 7-item questionnaires ask about a participant’s subjective 
level of fatigue, cognitive performance, and frustration occurring during each of the three experimental 
cognitive neuroscience paradigms described below. The debriefing questionnaires provide a means to 
directly compare self-reported and objectively measured cognitive abilities. 
  IQ & Neuropsychological Assessments 
  Wechsler Abbreviated Scale of Intelligence (WASI). Full-scale IQ was approximated utilizing 
two subtests from the WASI: Matrix Reasoning and Vocabulary.  
  DKEFS Trail Making Test: The DKEFS (Baron, 2004) Trail Making Test is a paper & pencil 
test consisting of five conditions meant to assess motor functioning & speed, as well as general aspects of 
executive functioning including inhibition and interference control. All five conditions were administered 
to participants. Condition one is a visual search and cancellation task whereby participants were asked to 
find and cross-out any number threes they can locate. In conditions two and three, participants must draw 
a line between the dots in order to connect a series of letters or numbers on a page in sequential order. 
Condition four required participants to alternate or switch between connecting a number and a letter in 
order. The final condition simply required participants to connect a series of dots. All conditions were 
timed and participants were asked to complete each task as quickly as they could without making 
mistakes. Conditions 1, 3, and 4 were included in analyses. 
  DKEFS Color-Word Interference Test: The DKEFS Color-Word Interference Test assesses 
verbal processing and general aspects of executive functioning including inhibitory control and cognitive 
flexibility. In condition one, participants were asked to look at patches of color and say the color aloud. 
Condition two asked the participants to simply read words aloud. In condition three, participants read 
words printed in different ink colors. Some words are color words and the ink color can be either the same 
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as the word (congruent) or different (incongruent). The final condition is similar to condition four, except 
words can also appear in a box, where the word and not the ink color the word is printed in is read aloud. 
  Hopkins Verbal Learning Test-Revised (HVLT): The Hopkins Verbal Learning Test-Revised 
(Belkonen, 2011) assesses verbal learning and memory through semantic categorization and recall. In the 
sequential learning trials, participants were presented with a series of words belonging to one of three 
categories (animals; lodging; gems) and asked to remember them. Participants, must then repeat as many 
words as they can remember, in any order. After a 20-minute delay, participants were asked to remember 
and list as many words as they could, in any order, using free recall. In the final discrimination condition 
immediately administered after the free recall portion, participants were presented with a set of words that 
had either been learned previously or were new words that belonged to the same category. Participants 
responded whether or not they were previously presented with the word by responding yes or no.  
  D2 Test of Attention: The d2 Test of Attention assesses selective and sustained visual attention, 
concentration, and processing speed (Bates & Lemay, 2004). Participants attempted to discriminate 
amongst visually similar stimuli to isolate specific features. After a single untimed practice trial, 
participants saw 14 lines with the letters “d” and “p” interspersed. Each letter has a variable number of 
dashed lines; the task is to cross-out only “d’s” with two dashes while ignoring “d’s” with more of less 
than two dashes and “p’s” altogether. The main task is timed and consists of 14 lines. For each line a 
participant had 20 seconds (s). 
 
Experimental Cognitive Neuroscience Paradigms 
Relational and Item Specific Encoding Task (RISE): The RISE task (Ragland et al., 2012) is a 
2-part encoding and retrieval episodic memory task comprised of item-specific and relational item-pair 
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conditions (Figure 4). The RISE task uses a set of 
144 visual stimuli representing common 
everyday objects and scenes selected from a 
public repository of 2,500 color images 
(http://cvcl.mit.edu/MM/).  
  Part 1: Item and relational 
encoding.  Part 1 had 6 total blocks. 3 item-
specific blocks and 3 relational encoding 
blocks were presented in alternating order 
(see Figure 4; top). Before each block, 
instructions were presented for 3s to remind 
participants which condition was coming 
next. In the item encoding blocks, each block contained 12 trials (12 visual stimuli per trial; 36 total 
items). Stimuli were presented one at a time for a duration of 2s with a 1s interval between stimulus 
presentation. During the interval a white fixation cross was presented at the center of the screen. During 
the 2s stimulus presentation, participants were asked to decide whether or not an item is “living” or “non-
living.” Participants indicated their decision with a 2-button response (1=Yes; 2=No) using their right-
hand. Relational encoding blocks contained 6 trials (6 stimulus-pairs; 18 total pairs). Pairs of stimuli were 
presented for 4s each with a 1s interval between presentation of the stimuli. During the 4s stimulus-pair 
presentation, participants were asked to decide whether one item can fit inside the other. Participants 
indicated their decision with a 2-button response (1=Yes; 2=No) using their right-hand. Participants were 
asked to respond as quickly and as accurately as they can. Training: Participants completed a separate 
practice run of 4 trials for both the item and relational encoding condition to ensure they understood the 
directions and knew which keys to press. Stimuli used during the practice were not repeated during the 
main task. 
  Part 2: Item and relational retrieval. Part 2 was comprised of 2 blocks, 1 for the item-specific 




retrieval condition and 1 for the relational retrieval condition (see Figure 4; bottom). Before each block, 
instructions were read aloud to a participant. The item retrieval block contained 144 trials (72 “new” 
visual items intermixed with 72 “old” visual items (e.g. foils) from part 1). In the item-specific retrieval 
condition participants were asked to decide whether or not an item was seen previously during part 1, and 
to rate their level of confidence (low, medium, high) in their decision. Participants marked an item as old 
(seen in part 1) via a left-hand response and pressed one of three keys to indicate their level of confidence 
in their decision (a=low; s=medium; d=high). A right-hand response marked an item as new (not seen 
before during the task) via a right-hand response using one of the three keys (j=high; k=medium; l=low). 
Stimuli were presented for a maximum of 10s, however, after a participant made a response the trial 
ended after 1.5s. Each trial was followed by a fixation cross for 1s. Participants were told to make their 
responses as quickly and accurately as they can. In the relational retrieval condition, a participant had to 
decide whether or not a pair of objects had been seen together previously during the relational encoding 
condition in part 1. Stimuli consisted of 18 stimulus pairs from the relational encoding conditions in part 
1 and 18 new stimulus pairings (items not previously paired together). Stimuli were presented for a 
maximum of 10s, during which participants responded with a 2-button (1=Yes; 2=No) response (no 
confidence judgment required). Once a participant made a response, the trial ended after 1.5s. Each trial 
was followed by a fixation cross for 1s. Participants were told to make their responses as quickly and 
accurately as they can. Training: Participants completed a separate practice run before each retrieval 
condition. Each run consisted of 10 trials to ensure they understood the directions and knew which keys 
to press. Stimuli used during the practice were not repeated during the main task.  
  Dot Pattern Expectancy Task (DPX): The DPX (Henderson et al., 2012) is a modified 
continuous performance task that uses dot patterns instead of letters (Figure 5). The DPX is designed to 
distinguish between multiple cognitive component processes including sustained and selective attention, 
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working memory, response control, and 
processing speed. In this task, participants 
viewed a series of randomly presented 
images. Stimuli are a series of 3-5 white or 
blue dots arranged in a particular pattern. A 
total of four different patterns of dots are 
possible. Dots are labeled as A, B (the 
cues) and X, Y (the probes). Each trial 
consisted of an initial cue followed by a 
probe (AX, AY, BX, BY). Participants were instructed to look for a target sequence (AX). The target 
sequence is considered a valid (AX) trial and all other combinations are invalid (AY; BX; BY) trial-type 
pairs. Participants responded with one of two keys (j or k). For the valid target (AX) sequence, 
participants were instructed to press the ‘k’ key. For all other invalid responses, a participant was 
instructed to press the ‘j’ key.  
  The DPX task consisted of 4 blocks of 40 trials (160 total). Cue trials had a 3s duration; stimuli 
were presented for 1s, followed by a fixation cross for 2s. Participants had 1.4s to respond. Probe trials 
are 2.4s in duration; stimuli were presented for .5s followed by a fixation cross for 1.9s Participants had a 
total of .9s to respond. Late responses were recorded. After each allotted response window, 1 of 3 tones 
(buzz, knock, beep) was presented as audio feedback. These tones indicated whether or not a response 
was correct, incorrect, or late respectively. Participants were instructed to make their responses as quickly 
as they can (Henderson et al., 2012). Training: Before test administration, participants completed a series 
of training runs to ensure comprehension of task instructions. Training: In this task, a training run is 
identical to the test condition. Participants were instructed to try and achieve an overall accuracy of 75% 
before moving on to the primary assessment. A maximum of 5 practice runs was administered. 
Figure 5. Dot Pattern Expectancy Task 
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Participants were excluded if they did not achieve an accuracy level equal to or greater than 50%. 
  Cued Cognitive Flexibility Task (CCF): The CCF is designed to assess multiple components of 
executive function including cognitive flexibility and interference control as well as implicit learning. In 
this task, participants viewed a series of randomly presented digits (0-9; excluding 5) and were cued by 
the digit’s color to make a judgment of either magnitude (red: greater or less than 5) or parity (blue: odd 
or even) with a left or right button press (Figure 6). Trials are either ‘hold’ (same judgment as the 
previous trial) or ‘switch’ (other judgment) trials. Simultaneously, trials could be either ‘congruent’ or 
‘incongruent’. The majority of trials were congruent whereby the stimulus presented requires the same 
button press as the preceding trials. For incongruent trials, a different response than the previous trial 
would be expected. For example, during a congruent trial, a red 8 (greater than five) might be followed by 
a blue 8 (even) and elicit a right button press. During an incongruent trial, a red 7 (greater than five) might 
be followed by blue 7 (odd), would indicate a right button press followed by a [less expected] left button 
response.  
  This task was comprised of 3 blocks each 
containing 49 trials (147 trials total). Block order was 
counterbalanced per participant. The proportion of 
switch trials was manipulated such that a task block 
could have a low (.25), medium (.5) or high (.75) 
proportion of switches. Stimuli were randomly 
presented for 1.2s. Following a stimulus, a fixation 
cross was displayed for a randomized duration set to 
an inter-trial interval ranging from 1.25s to 2s. 
Participants had a total of 2s to respond and late 
responses were recorded. Participants were instructed to 
make their responses as quickly as they can (Chiu & Egner, 2017). Training: Prior to test administration, 
participants completed a series of training runs to ensure comprehension of task instructions. During 
Figure 6. Cued Cognitive Flexibility Task 
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training the proportion of switches was held constant at 50%. The CCF has not been tested in older adults 
and patients, therefore the target accuracy level was be slightly adjusted from 80% as in Chiu & Egner 
(2017) to 75%. Participants were instructed to try and achieve an overall accuracy level of 75% before 
moving on to the primary assessment. A maximum of 5 practice runs was administered. Participants were 
excluded if they did not achieve an accuracy equal to or greater than 50%. 
 
Machine Learning & Random Forest Classification  
The random forest (see Figure 3) is designed to handle complex high-dimensional interactions 
with no restraints on the types of features included for prediction (i.e. categorical, numerical) and are thus 
well-suited for combining factors across clinical, biological and cognitive domains (Altman & 
Krzywinski, 2017; Breiman, 2001; Denisko & Hoffman, 2018). To assess how well BCS could be 
distinguished from healthy women participants, the current study utilized 69 total features from the set of 
questionnaires and cognitive assessments as described above (see Supplemental Table 1). Prior to random 
forest modeling, a series of data quality checks were performed as described in the following section. 
  Exploratory Data Analysis (EDA). While no ‘preprocessing’ or extensive ‘data wrangling’ is 
necessary given the non-parametric nature of machine learning algorithms (meaning there is no 
dependency or reliance on linear assumptions), variable distributions were inspected to ensure a degree of 
purity in the data before constructing random forest models. As part of EDA, features with minimal 
variance and/or exhibiting a high degree of correlation (r ≥ .85) were excised from further analysis. The 
cutoff used to define highly correlated variables is chosen based on previous literature; it should be noted 
the value of .85 is somewhat arbitrary and range of thresholds (.70-.95) can be tested (Dormann et al., 
2013). This step helped to ensure classification accuracies and feature importance rankings were not 
biased by features that exhibited highly similar distributions and had a high degree of multicollinearity. 
High multicollinearity may lead to bias during the random sampling process given similar features 
important for classification are likely to be overrepresented due to repeated selection. Features that lack 
variability cannot be used to differentiate items into their respective classes and only serve to increase 
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computational time. Such a framework permitted the comprehensive modeling of linear and non-linear 
multivariate dependencies between cognitive components, influential contributing risk factors (e.g. sleep, 
fatigue, depression, etc.) and demographic variables of interest (see Table 1). The dataset was inspected 
for missing values. Missing data were imputed using the random forest imputation (Breiman, 2001). 
Items not excluded during EDA were used as predictive features used to distinguish BCS from HC using 
random forest classification modeling. 
Random Forest Application & Model Performance. For supervised classification problems, a 
series of decision trees are constructed to predict an a priori defined class label (BCS or HC) for a given 
set of observations. The set of decision trees/models are aggregated to generate forests which minimize a 
cost function. The Gini impurity index is a built-in cost function that measures how “pure” a set of 
classifications are for a decision point at each root node (see figure 2) within a given decision tree. 
Specifically, it measures how consistently a feature splits data into their respective classes across a set of 
decision trees and thus is the probability of misclassifying new data. Minimizing the cost function ensures 
groups are maximally separated (i.e. better classification accuracy). To minimize sampling bias, and 
ensure all features and observations have been modeled in the random forest, k-fold cross-validation was 
performed. K-fold cross-validation randomly partitions data into k independent subsamples which are 
then used to train and test model performance. 5-fold cross-validation is commonly used in conjunction 
with the random forest when the sample size is not sufficiently large (Borra & Di Ciaccio, 2010; Steven 
L. Salzberg, 1997). When combined with the built-in bootstrapping technique (see Modeling & 
Prediction), cross-validation helps to further reduce overfitting and sampling bias. With 5-fold cross-
validation, a dataset is randomly partitioned into 5 subsamples. On each fold, a single test sample that has 
not been used to train the random forest is set aside and used to test model performance. This process 
repeats k times ensuring all samples have been used to train and test the random forest. Within each fold, 
the model parameters (the set of decision rules) are applied to data from an independent test set of 
observations (e.g. data not used to construct the model). Here, each new observation (participant) in the 
held-out test set is “run” down the tree and assigned a label (see Figure 3). Classification accuracy 
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quantifies how many times an observation was correctly classified as BCS or HC across each fold of 
cross-validation). In addition to classification accuracy, the No Information Rate (NIR) is a statistic based 
on a one-sided binomial test of proportions that compares observed model accuracy to that expected by 
chance given the total number of possible true cases. That is, a p-value (p-NIR) under the specified alpha 
(.05) is used to indicate if the cross-validated model accuracy is statistically significant as compared to the 
total number of sampled cases in the majority class (e.g. positive class; BCS).  Typically, NIR is used to 
assess model performance in unbalanced datasets where the number of observations between classes is 
not equal. Here, NIR was used to assess sampling bias, whereby the proportion of classes may differ 
across cross-validation folds. As a final step, accuracy-based classification performance was assessed via 
permutation testing, whereby the distribution of model misclassification rates, averaged across all 
independent (e.g. held out) test sets, is compared to an empirically generated null-distribution of 
classification models (e.g. random chance). To generate an empirical null-model derived from the current 
dataset, each step in the random forest process is repeated and class labels (e.g. group status; BCS vs. HC) 
are randomly permuted or shuffled. The number of permutations was set to 1000 (Breiman, 2001; Chen & 
Ishwaran, 2012; Denisko & Hoffman, 2018; Feczko et al., 2018). 
Model Comparisons. Multiple random forest models, each containing an a priori defined subset 
of features, were (1) assessed for their respective ability to classify BCS from HC, (2) compared to a 
single full model comprised of all available features, and (3) compared to a final reduced model 
containing only the highest-ranked features. By using all available features within a given dataset, every 
possible combination, or interaction between features, becomes factored into a given model’s 
classification performance. This process was taken to help identify the most important combination of 
predictors. In this instance, each predictor is contingent on the number of possible interactions that can 
occur with features from different categories (e.g. demographic and self-report, neuropsychological, and 
experimental cognitive neuroscience metrics). As an example, in BCS it is hypothesized, but untested, 
that certain confounding factors such as age, fatigue and depression relate to cognitive performance on 
both specific and general components of cognition. Using all available features within the random forest 
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directly tests such hypotheses. By considering multiple reduced models, each containing a specific subset 
of features, it is possible to 1) assess how important a particular feature is independent of other potentially 
confounding factors, and 2) how important an overall category is to classification.  
As in Kesler, Rao, Blayney, et al. (2017), model sensitivity (true positive rate) and specificity 
(true negative rate) can be quantified across a range of classification thresholds using the area under the 
receiver operating curve (AUROC). The AUROC is a single numerical summary describing the 
proportion of correctly identified BCS cases (sensitivity, or true positive rate) to those correctly classified 
as HC (specificity, or precision) for a given classification model. The AUROC was formally compared 
between all models using the non-parametric Delong test (DeLong et al., 1988). Pairwise comparisons 
were corrected using the Benjamini-Hochberg False-Discovery Rate (FDR) (Benjamini & Hochberg, 
1995). Two additional ROC-based metrics are reported that characterize model performance based on the 
distribution of predicted class probabilities as opposed to overall model accuracy. The Brier score is a 
cost-function that indicates how well a set of predicted probabilities match their respective classes on 
average (Brier, 1950). Lower Brier scores (0-1) indicate better model performance. Informedness 
represents how informed a set of predictions are relative to chance and is defined as the difference 
between true and false positive rates. Informedness values range from -1 to 1 with zero representing 
chance. Values less than chance indicate a model which is strongly biased toward the negative class 
resulting in a greater proportion of false positive and false negative predictions. 
The ability to compare multiple models using a specific set of performance evaluation criteria 
permits a comprehensive assessment of (1) demographic & self-report data, (2) performance on 
neuropsychological assessments, and (3) performance on experimental cognitive neuroscience tasks for 
their respective, and joint ability to differentiate BCS from HC.
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ANALYSES & HYPOTHESES 
 
 
Primary Aim 1: Determine if individuals suffering from chemotherapy-related cognitive 
impairment can be distinguished from age-matched healthy control participants. This aim 
systematically addresses limitations and inconsistencies inherent to previous research regarding the 
precise nature of CRCI in BCS by modeling high-dimensional non-linearities between factors implicated 
in CRCI. All available features surviving the initial EDA served as predictors in the random forest model 
and were used to classify BCS vs HC. Although groups were matched on age and IQ, these measures 
were included as features of interest given that minor variations in age or IQ may interact with other 
features within a given model and subsample of participants. From this full-model, obtained estimates of 
average classification accuracy, ROC-based metrics, and variable importance estimated via 5-fold cross-
validation are reported. Permutation testing was used to gage model performance compared to random 
chance (Feczko et al., 2018; Rudolph et al., 2018). 
  Hypotheses: I hypothesized that a comprehensive modeling approach would result in a greater 
than chance random forest classification model that accurately distinguishes BCS from HC. Overall, 
compared to neuropsychological assessment summary scores, I hypothesized that performance metrics 
from experimental cognitive neuroscience paradigms would be weighted more heavily in classification 
models (i.e. greater variable importance contributing to model accuracy). Based on previous literature, I 
hypothesized that fatigue and depression would rank higher in importance than other self-reported 
physical and health-related risk factors. I additionally hypothesized that response time would discriminate 
groups better than accuracy-based metrics on average.  
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Primary Aim 2: Establish if cognitive neuroscience tasks are more sensitive and specific than 
traditional neuropsychological assessments to detect subtle deficits in cognitive functioning in BCS 
independent of confounding variables. Three separate random forest models comprising (1) 
neuropsychological assessments, (2) experimental cognitive neuroscience and (3) self-report metrics were 
assessed for their respective ability to independently classify BCS from HC. This approach permitted 
direct assessment of metrics within a given model and comparisons of overall classification accuracy 
between models. Classification and ROC-based metrics were assessed as in Primary Aim 1 and compared 
between each of model to determine which set of features most accurately distinguishes BCS from HC.  
  Hypotheses: It was expected that the overall classification accuracy would be greater for 
experimental cognitive neuroscience paradigms as compared to neuropsychological assessments. Given 
consistent self-reported cognitive deficits in the CRCI literature, I hypothesized that the self-report model 
would produce greater than chance classification.  
  Exploratory Aim 3: Assess and compare model performance and variable importance to isolate 
the most informative and predictive features of CRCI. Individuals can be classified differently 
depending on the combinations of variables used in a given classification model. It was therefore 
important to assess both a given feature’s relative importance (primary aim 2; individual models), and 
overall importance (primary aim 1; full model) when using a combined feature set to distinguish BCS 
from. HC. To identify the highest ranked features across all models, ranked variable importance weights 
were assessed. A final model comprised of the top 20 predictive features from the full model (model 1) 
was used to assess the highest level of classification accuracy that could be achieved. In addition, it was 
important to assess which of the most predictive features were statistically different between groups 
irrespective of any higher-order dependencies with other variables. Post-hoc two-sided independent t-tests 
(alpha level set at .05) were conducted to test for univariate group mean differences. Descriptive statistics 
and (uncorrected) pairwise statistical comparisons are provided for all features in Supplemental Table 2. 
All pairwise t-tests were additionally corrected for multiple comparisons using the FDR (Benjamini & 






Exploratory data analysis. No features exhibited near-zero variance. Four features from the 
DKEFs trail-making and Stroop color-word assessments exhibited low-cardinality including color-word 
inhibition errors, and trail-making errors on the scanning and switching conditions (sequence and set-loss 
errors). Although low-cardinality will not impede classification performance per se, continuous features 
with a limited set of unique values or levels may exhibit ceiling effects. Multicollinearity was addressed 
by removing features with pairwise correlation coefficients above .85 (see Supplemental Figures 1, 2, and 
3 for correlation matrices) before analyses. Excluded features possessed strong multivariate linear 
relationships and were considered redundant (see Methods). As expected, Beck depression scores were 
highly correlated with many self-report metrics including perceived stress from the Perceived Stress 
Scale, and emotional stress as measured by the Multidimensional Fatigue Scale. Additionally, measures 
of physical activity and motivation from the Multidimensional Fatigue Scale, and a measure of general 
processing speed from the d2 Test of Attention, were also excluded from analyses due to 
multicollinearity. Naturally, however, excluded variables can be associated with features that strongly 
contribute to the classification of BCS experiencing CRCI from HC (see Discussion). The exclusion of 
redundant features resulted in a final set of 65 features to be used for classification. 
The random forest is known to be robust to the influence of outliers and non-normally distributed 
features (Breiman, 2001; Denisko & Hoffman, 2018). However, to enable visualization of average group 
differences, and to help isolate any potential scores that may be implausible or unlikely given the data, 
group boxplots for each set of assessments are provided (see Supplemental Figures 3, 4, and 5). Finally, 
the dataset was inspected for missing values. 1.1% of data points were missing at random. Before 
classification, any missing values were imputed using the built-in imputation procedure provided with the   
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randomForest package in R (Liaw and Wiener, 2002) as described in Methods. Given the sparsity of 
missing values, it is unlikely that missing data imputation had any substantial effect on the current 
analyses. 
Random Forest Classification. As described in the Methods, four primary classification models 
were constructed. Model 1 comprised all features remaining after exploratory data analysis to determine if 
individual BCS suffering from chemotherapy-related cognitive impairment could be distinguished from 
age-matched healthy control participants (Primary Aim 1). Next, three models utilized independent 
feature sets to establish if cognitive neuroscience tasks are more sensitive to CRCI than traditional 
neuropsychological assessments (Primary Aim 2). Model 2 included measures from demographic, 
clinical, and psycho-social data, model 3 was comprised of metrics from neuropsychological assessments, 
and model 4 contained metrics from experimental cognitive neuroscience paradigms. To isolate the most 
informative and predictive features of CRCI (Exploratory Aim 3), variable importance was assessed for 
each model. Additionally, a final reduced model (model 5) that comprised the top 20 ranked features was 
constructed. All models were formally compared. A detailed breakdown of model performance is 
provided in Table 2 and Figure 7. Feature importance rankings for each model are provided in Figure 8. 
 
Primary Aim 1 
Model 1. A combination of metrics from models 1-3 classified 73% of individuals correctly 
(14/20 BCS; 15/20 HC). ROC analysis (Figure 7): AUROC = .78 (CI: .64-.92); sensitivity = .75 (CI: .53-
.89); specificity = .75 (CI: .53-.89), Brier-score = .217. Permutation testing (1000 iterations) indicated 
model 1 was significant compared to random chance (p = .037). Cross-validation identified 2 as the 
optimal number features to be randomly selected for splitting at each node in a given decision tree. The 
10 highest-ranked predictors included a combination of 1) self-report measures indexing fatigue, sleep, 
stress, and distractibility, 2) objective measures of cognitive performance from the experimental cognitive 
neuroscience paradigms indexing item and relational memory encoding, as well as sustained and selective 
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attention, from the RISE and DPX, and 3) memory recall and inhibitory control from the HVLT and 
DKEFs color-word neuropsychological assessments (see Figure 8, left panel). 
 
Primary Aim 2 
Model 2. A combination of demographic, clinical, and psycho-social data classified 65% of 
individuals correctly (10 BCS; 16 HC). ROC analysis (Figure 7): AUROC = .70 (CI: .64-.92); sensitivity 
= .50 (CI: .30-.70); specificity = .80 (CI: .58-.92), Brier-score = .226. The optimal number features 
randomly selected for splitting at each node within a given decision tree (e.g. the mtry hyperparameter) 
identified via cross-validation was 2. Permutation testing (1000 iterations) indicated model 2 was 
significant compared to random chance (p = .017). The 5 highest-ranked predictors included measures 
indexing self-reported levels of fatigue, distractibility, stress, and perceived difficulty with the CCF task 
(see Figure 8; panel b). 
Model 3. A combination of several commonly administered neuropsychological assessments 
classified 53% of individuals correctly (12/20 BCS; 9/20 HC). ROC analysis (Figure 7): AUROC = .60 
(CI: .42-.78); sensitivity = .60 (CI: .39-.78); specificity = .45 (CI: .26-.66), Brier-score = .243. 
Permutation testing (1000 iterations) indicated model 3 was not significant compared to random chance (p 
= .075). Cross-validation selected 15 as the optimal number of features used for splitting. The 5 highest-
ranked predictors included measures indexing levels of selective attention and concentration performance 
on the D2 test of Attention, and memory recall via the HVLT, and performance on the DKEF’s color-
word inhibition condition (see Figure 8; panel c). 
Model 4. A combination of metrics from experimental cognitive neuroscience paradigms 
classified 60% of individuals correctly (11/20 BCS; 13/20 HC). ROC analysis (Figure 7): AUROC = .64 
(CI: .47-.81); sensitivity = .55 (CI: .34-.74); specificity = .65 (CI: .43-.82), Brier-score = .240. 
Permutation testing (1000 iterations) indicated model 4 was not significant compared to random chance (p 
= .069). Cross-validation identified 2 as the optimal number features to be randomly selected for splitting 
at each node in a given decision tree. The 5 highest-ranked predictors included both accuracy and 
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response time measures indexing item and relational memory encoding performance on the RISE task, 
and response time metrics of sustained attention and working memory from the DPX and CCF tasks (see 
Figure 8; panel d). 
Exploratory Aim 3 
Model 5. A model comprised of the top 20 predictors classified 80% of individuals correctly 
(17/20 BCS; 15/20 HC). ROC analysis (Figure 7): AUROC = .85 (CI: .73-.97); sensitivity = .85 (CI: .64-
.95); specificity = .75 (CI: .53-.89); Brier-score = .176. Permutation testing (1000 iterations) indicated 
Figure 7. ROC analyses and cross-validated classification performance. Results for models 1-4 
(full aggregate model (model 1, red); self-report measures (model 2, blue); neuropsychological 
assessments (model 3, grey); experimental cognitive neuroscience metrics (model 4, yellow)) are 
ranked and visualized in parallel. AUROC-based classification performance is presented over a 
range of possible decision thresholds (0-1) in panel a. The light-grey line situated on the diagonal 
represents a classification accuracy at chance level (50%). True positive rate (e.g. sensitivity) is 
on the y-axis and false positive rate (e.g. specificity) is on the x-axis. Panels b and c depict the 




model 2 was significant compared to random chance (p = .002). Cross-validation identified 2 as the 
optimal number features to be randomly selected for splitting at each node in a given decision tree. All 
predictors in this model have been preselected based on prior model performance and thus contribute to 




Figure 8. Cross-validated feature performance. Feature importance ranking are displayed for 
models 1-4 (full aggregate model (model 1, red); self-report measures (model 2, blue); 
neuropsychological assessments (model 3, grey); experimental cognitive neuroscience metrics 
(model 4, yellow)). Measures are scaled to 100. Scaled variable importance measures represent 





As expected, model 5 (final reduced model) improved overall accuracy and provided a balanced 
sensitivity and specificity compared to all other models on average. The performance of model 5 was 
significantly different from models 2-4, which were constructed using independent feature sets (model 2 
(self-report): D = -2.170, p = .030, p-FDR = .043; model 3 (neuropsychological): D = -4.628, p < .001, p-
FDR < .001; model 4 (experimental cognitive neuroscience): D = -3.642, p < .001, p-FDR = .001). Model 
5’s performance was not significantly different from model 1 (full model: D = -1.626, p = .104, p-FDR = 
.104). Additionally, model 1 (full model) was statistically different from model 3 (neuropsychological; D 
= -3.6325, p < .001, p-FDR = .020) and model 4 (experimental cognitive neuroscience; D = -2.4236, p = 
.015; p-FDR = .030), but was not significantly different from model 2 (self-report: D = -0.811, p = .417, 
p-FDR = .417). Models 3 (neuropsychological) and 4 (experimental cognitive neuroscience) were not 
significantly different from one another (D = -1.4386, p = .150, p-FDR = .167). All model comparison 
statistics were generated using 1000 bootstrap iterations (see Methods). 













AUROC .78 .70 .60 .64 .85 
AUROC (SD) (.64-.92) (.54-.86) (.42-.78) (.47-.81) (.73-.97) 
Brier-score .217 .226 .243 .240 .176 
Informedness .50 .30 .05 .20 .60 
ACC .73 0.68 .53 .60 .80 
ACC 95% CI (.56, .85) (.51, .81) (.36, .69) (.43, .75) (.64, .91) 
p-NIR .003 .019 .430 .134 < .001 
Sensitivity 0.70 0.60 0.60 0.55 .85 
Specificity 0.75 0.75 0.45 0.65 .75 
Permutation p .037 .017 .75 .067 .002 
 
Table 2. Roc analysis and cross-validated classification results. Results from all models are 
presented together to promote efficient comparison. The results presented in the table indicate 





Univariate Group Comparisons 
Independent two-tailed t-tests (uncorrected) tested for group mean differences for all continuous 
features (see Methods for rationale). In total, 10 out of 65 features (15%) were statistically different 
(alpha <= .05; uncorrected) between BCS and HC. Measures included (1) self-reported levels of stress, 
forgetfulness and distractibility, and mental and emotional health, (2) neuropsychological measures of 
concentration performance, and (3) item and relational memory encoding, and working memory. No 
group differences survived FDR correction for multiple comparisons (see Supplemental Table 2).
Figure 9. Final model performance & feature importance rankings. Results from model 5 are 
integrated with results from model 1-4 (full aggregate model (model 1, red); self-report measures 
(model 2, blue); neuropsychological assessments (model 3, grey); experimental cognitive 
neuroscience metrics (model 4, yellow)) as depicted in Figure 8 and 9. In the left panel, true 
positive rate (e.g. sensitivity) is on the y-axis and false positive rate (e.g. specificity) is on the x-
axis. Feature importance for the final reduced model is depicted on the right. This figure 
demonstrates the superior performance of both the full and final reduced models to produce 
accurate and balance classification of BCS and HC driven by a combination of metrics that 





The true prevalence of individual breast cancer survivors who may experience CRCI at some 
point before, during, and after treatment with chemotherapy is currently uncertain. The primary goals of 
this study were (1) to provide a comprehensive assessment of CRCI, and (2) to determine the probability 
that BCS within 1-12 months of treatment with chemotherapy could be accurately classified from HC 
based on the assessment of self-report measures, neuropsychological assessments commonly used in 
studies of CRCI, and three experimental cognitive neuroscience-inspired paradigms independently and in 
aggregate. Classification models were constructed to assess individual patterns of responses on self-report 
measures and cognitive tasks to help bridge the gap between subjectively reported and objectively 
measured cognitive impairment. Given the inconsistency regarding the presence and magnitude of 
cognitive impairment in women BCS, and prevalence of normative cognitive decline observed on average 
in aging individuals, classification models were optimized according to receiver operating characteristics 
to ensure a relative balance between specificity and sensitivity of performance measures. 
 
Classification Performance & Feature Importance 
As expected, self-report measures (model 2) were able to distinguish between BCS and HC. 
Consistent with prior studies, high levels of stress, fatigue, and poor sleep were among the top-ranked 
features. Self-reported symptoms of depression measured by the Beck Depression Inventory were 
significantly higher in BCS. Beck depression scores were excluded prior to analyses due to a high degree 
of multicollinearity. Thus, as highlighted within the introduction, by proxy, symptoms of depression are 
also important for identifying individual BCS who may be experiencing CRCI.  
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Cognition. Assessed independently, overall, traditional neuropsychological assessments (model 
3) provided little information regarding cognitive impairment in either healthy controls or breast cancer 
survivors. However, measures assessing memory recall (HVLT) and attention (e.g. concentration; D2 
Test of Attention) consistently ranked higher than other neuropsychological measures in the classification 
of BCS from HC. Interestingly, of these two measures, mean group differences (uncorrected t-tests; see 
Supplemental Table 2) were found for concentration performance only, with BCS performing more 
poorly on average.  
A similar picture emerged when the top-performing metrics from model 3 (neuropsychological) 
were combined with self-report assessments and experimental cognitive neuroscience metrics in the full 
(model 1) and final reduced (model 5) models. Here, self-reported levels of fatigue and distractibility, and 
cognitive measures that index sustained and selective attention as well as memory encoding and recall, 
were consistently ranked high in importance. This was particularly the case in the final reduced model 
(model 5).  
In model 5 metrics from experimental cognitive paradigms (model 4) were weighted considerably 
higher than neuropsychological assessments. In models 4 and 5, high ranking features from experimental 
cognitive neuroscience paradigms measure specific aspects of sustained and selective attention along with 
memory encoding as opposed to memory recall. These results are of particular interest as studies 
conducted in both BCS (Li et al., 2016) and in aging individuals without cancer (Kim & Giovanello, 
2011), have found that difficulties in memory retention and recall, most commonly reported in BCS (e.g. 
forgetfulness), may stem from impairments in attention. That is, consistent with high levels of self-
reported distractibility, deficits in sustained and selective attention may negatively impact memory 
encoding which in turn alters subsequent memory retrieval. This interpretation is also in line with 
speculations made by Horowitz and colleagues (2018) based on previous CRICI research as highlighted 
within the introduction. 
As depicted in Figure 10, an association between accurate recall on the HVLT, and slower 
response times on the relational retrieval portion of the RISE task, may indicate that deficits in memory 
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recall are present in BCS, but that this observation may be more reliable when the two assessments are 
considered together. An additional interpretation is that speed-accuracy trade-offs, present in BCS, may 
explain the association between the HVLT and the RISE tasks in the current sample. Likewise, in BCS, 
better performance on the DKEFs inhibition task shows an unexpected positive association with response 
times on the DPX AY condition where participants must inhibit prepotent responses to invalid/invalid 
stimulus pairs. Again, such a finding may suggest that BCS are more likely to engage in cognitive 
strategies that maximize performance at the cost of speed. Conversely, however, measures of sustained 
and selective attention on the DPX and CCF paradigms do not appear to be associated with concentration 
Figure 10. Associations between neuropsychological and experimental cognitive 
neuroscience-based features that were retained in the final reduced model. Here, a pairs plot is 
used to show (1) group-wise distributions of, and (2) linear associations between the set of 
neuropsychological and experimental cognitive neuroscience features that were included in the 
final reduced model (model 5). The number of potential interactions present across the final set 
of metrics within and between groups is visualized in the lower triangle of the graph. Cells that 
are outlined in black represent specific comparisons between neuropsychological assessments 
and experimental cognitive paradigms that measure similar cognitive processes (see Discussion). 
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performance on the d2 Test of Attention. This result may suggest that each measure is tapping a different 
mechanism of attention that interacts with other features in important ways contributing to better overall 
classification of BCS from HC. 
Assessing group mean differences using a standard two-sample t-test (uncorrected), a small 
fraction (11/65) of features fell at or under alpha (.05). As expected, self-reported levels of physical and 
emotional stress and depression were greater in BCS, as were measures that indicate difficulties with 
memory and attention (cfq: forgetfulness and distractibility). Two general measures of attention and 
cognitive flexibility (d2: concentration performance; DKEFs Trail-Making: Set-loss errors) from the 
neuropsychological battery and three specific measures of memory encoding and working memory from 
experimental cognitive paradigms indicated lower average performance in BCS. Except for set-loss errors 
on the DKEFs Trail-Making Test, features indicating potential group mean differences were ranked high 
on variable importance for classifying BCS from HC.  
Regardless of the neuropsychological assessment under consideration, count-based features that 
index the number of item-level errors were either at or near ceiling, having low-discriminability across 
observations. As discussed within the introduction, the lack of discriminating power is concerning, and 
may potentially indicate measures with limited reliability for identifying CRCI (see EDA). Many 
neuropsychological assessments have been shown to suffer from ceiling effects. Ceiling effects can 
drastically affect statistical group comparisons and lead to unreliable parameter estimates. In the current 
data set, the presence of ceiling effects may further explain why errors on DKEFs assessments were not 
weighted heavily in any of the classification models (see Supplemental Table 1 and Supplemental Figure 
5).  
Other features implicated in CRCI, with no apparent group mean differences (fatigue, sleep, age, 
etc.) appear important for classifying individuals exhibiting some level of cognitive difficulty and may 
help identify tasks and conditions where there is a greater deal of individual cognitive variability within 
and between groups. Though preliminary, and caution is warranted with overinterpretation, results may 
highlight the importance of considering high-level interactions between distinct and overlapping cognitive 
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processes, that in combination with self-report measures, are better able to pinpoint specific cognitive 
impairments in BCS. All interpretations need to be further validated, and must be considered within the 
context of the study's limitations as discussed below. 
 
Limitations & Future Directions 
Sample size. Statistical learning algorithms such as the random forest have been shown to 
produce reliable estimates for large p small N problems when paired with cross-validation, particularly 
with respect to the conservative internal bootstrapped out-of-bag estimates. Previous studies assessing 
CRCI have successfully applied machine learning using similar sample sizes, albeit model accuracy was 
driven by the inclusion of biological markers as opposed to either self-reported or objectively measured 
cognition (S. R. Kesler et al., 2013; Shelli R. Kesler, Rao, Blayney, et al., 2017a). Nonetheless, the 
limited sample size and absence of an external validation set warrants particular caution and limits the 
amount of generalizability that can be inferred from the present findings. 
Sample specifics. The current sample of women BCS is comprised primarily of individuals who 
are either HER2-negative (PR+/ER+/HER2-) or triple-negative (PR-ER-/HER2-). HER2-positive tumors 
are known to be more aggressive in terms of unregulated cell growth (Minisini et al., 2004) and may carry 
a greater risk of metastases (Debiasi et al., 2018). Though results are mixed, some studies find that a 
HER2+ status is linked to poorer cognition (Ahles & Root, 2018). The true effect of tumor receptor-
subtype on the experience of CRCI may further depend on genetic polymorphisms related to certain 
enzymes and proteins such as catechol-O-methyl transferase, brain-derived neurotrophic factor, and 
apolipoprotein E. These markers have been implicated in both age- and cancer-related cognitive 
impairment and decline (Castel et al., 2017; Cheng et al., 2016). Additionally, all participants were fairly 
highly educated and 60% of the sample was white/Non-Hispanic (see Table 1). As a cross-sectional study 
it is not possible to assess the trajectory of impairment for a given individual, nor determine if and how 
baseline levels of cognitive ability before treatment impact the present results.  
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Assessing simple linear associations between time-since-treatment (with chemotherapy; see 
Figure 11) and self-reported cognitive impairment in the current sample suggests that with time, a portion 
of women BCS exhibit higher-levels of perceived cognitive impairment. However, the association 
between time-since-treatment and perceived cognitive impairment did not contribute to classification 
performance (Figure 11).  
 
Classification & Prediction 
Random forest classification models were assessed for their ability to accurately distinguish 
individual BCS from HC based on several performance metrics such as AUROC, sensitivity, specificity, 
and proper-scoring metrics such as the Brier score. Such methods are preferred to traditional accuracy 
when predictions are based on probability distributions (Brier, 1950; Bzdok & Meyer-Lindenberg, 2018; 
Pers et al., 2009; Steyerberg et al., 2010). Whether or not an individual is identified as a BCS, however, is 
based on a split decision threshold set at .5 (two-classes: HC or BCS). That is, a final classification 
decision is based on whether or not an individual is a BCS irrespective of the degree to which one may or 
may not possess a certain degree of cognitive impairment, and treats cognitive difficulties present in aging 
individuals without cancer as potential noise. As discussed in the introduction, the prevalence of CRCI in 
BCS can range anywhere from 35-75%. To date, research suggests that approximately 55% of women 
BCS are likely to experience some form cognitive impairment on average within a given sample (Joly et 
al., 2015; Shelli R. Kesler, Rao, Blayney, et al., 2017b; Shelli R. Kesler, Rao, Ray, et al., 2017; Wefel et 
al., 2010). Further, research suggests that the presence of cancer and treatment with chemotherapy may 
alter the magnitude of cognitive impairment and influence the rate of cognitive decline observed in aging 
individuals (Ahles & Hurria, 2018; Ahles & Root, 2018; Mandelblatt et al., 2016). Thus, a fixed threshold 
while useful in binary (yes | no) applications, such as detecting if a cancerous tumor is malignant or 
benign, is likely not the optimal solution in studies assessing CRCI. The threshold for determining the 
presence or magnitude of CRCI in BCS may be better informed through predictive modeling, where 
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consideration is given to both true positive and true negative rates, and the magnitude and stability of 
individual predicted probabilities can be assessed (Figures 13 & 14). 
 
While this study is not equipped to reliably address such concerns, results may suggest that 
detection rates can be improved when combining a subset of self-report measures, neuropsychological 
assessments, and experimental cognitive paradigms. In the current sample, using a combination of 
features (model 1 and 5), better detection can be achieved by slightly adjusting the decision threshold to 
Figure 11. Linear relationships between self-reported cognitive impairment, time since treatment, and 
predicted class probability. Panel a, b, and c depict linear associations between the likelihood of being 
correctly classified and higher average self-reported cognitive impairment in BCS (red dots) and HC (blue 
dots) as assessed with the CFQ and the set of debriefing questionnaires (DQ) for the experimental 
cognitive neuroscience tasks. In panels d, e, and f, linear associations are presented for time-since-
treatment and self-reported cognitive impairment in BCS (red dots). While associations appear present 
between self-reported cognitive impairment and both time-since-treatment and classification accuracy, no 
such relationship is present between classification accuracy and time-since-treatment. 
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.43 without affecting false-positive rates and retaining a relative balance of sensitivity and specificity (see 
Figure 13). Model 5 contained a limited set of high-ranking features from the full aggregate model. This 
model is likely biased and might be overfitting the data. However, model 5 provides an opportunity to (1) 
assess the potential level of classification and balance of sensitivity and specificity that can be achieved in 
the current sample (through cross-validation) by utilizing a combination of features that tap both general 
and specific cognitive domains, and (2) determine how stable a set of predictions are as depicted in 
Figures 13 and 14. Again, a larger study and external validation sample will be required to justify and 
substantiate such claims in the context of CRCI. 
Figure 12. Model predictions for individual participants. Individual predictions from each model (SR = 
Self-Report; NP = Neuropsychological; EXP = Experimental Cognitive Neuroscience; FULL = Full 
aggregate model; FINAL = Final reduced model) are displayed above. Filled in squares represent correct 
predictions (i.e. classification) for a given individual (HC = blue; BCS = Pink). Participants who were 
poorly classified across models are highlighted in red and blue. The red outline indicates participants who 
were only classified correctly by a single model. The blue outline indicates participants who were 
classified correctly in 2 of the 5 models. Figure 13 presents the actual probabilities that determined how 





Figure 13. Full aggregate (model 1) & final reduced model (model 5) cross-validated predicted class 
probabilities. Final class predictions (as depicted in Figure 12) for a given individual are based on the 
distribution of votes which are aggregated across an ensemble of decision trees within a given random 
forest model and average over each fold of cross-validation. The dashed black line represents a binary 
two-class threshold set to a default .5. The grey dashed line represents a data-driven threshold where the 
classification of BCS would be optimal based on model performance in the current data set. This graph 





Across a range of applications from image and tumor classification, to the prediction of early-
onset dementia, the random forest is amongst the top-performing machine learning classification and 
regression algorithms. In addition, the random forest algorithm has more recently been used to predict 
individual BCS who are more likely to experience short-term cognitive impairment based on a specific set 
of neuroimaging biomarkers. Despite this success, several tree-based extensions may hold particular 
promise for addressing the variability in cognitive performance at the level of an individual. Extreme 
gradient boosting (XGboost; Gao et al., 2018) and Case-Specific Random Forests (Xu et al., 2016), are 
adaptive algorithms that iteratively tune a given model as it is constructed based on each successive tree 
or based on the misclassification of a specific set of target individuals respectively (i.e. BCS). Other 
approaches combine models across different machine learning algorithms, a process known as stacking. 
However, such an approach is not guaranteed to improve predictive accuracy and comes at the cost of 
interpretability (Cao et al., 2019; Whalen & Pandey, 2013). Focusing on a single algorithm with 
demonstrated success across a range of scientific disciplines keeps the focus on the quality of a given 
dataset, and permits a comprehensive deconstruction of the multidimensional relationship between 
predictive features.  
 
Task Design 
The present work focused on assessing cognitive paradigms that are designed to tease apart 
specific cognitive processes and further can generate several performance metrics which permits a 
detailed analysis of within and between individual cognitive variability. As expected, metrics from the 
experimental paradigms were ranked higher in the most accurate classification models (models 4 and 5). 
While these results are promising, there is obvious room for improvement. As described within the 
introduction, the DPX, RISE, and CCF tasks have not been administered to adults over 60 or in BCS 
before this study. The DPX and RISE tasks come from the CINTRAC’s initiative and were optimized to 
detect and parse out specific contextual processing deficits in patients with schizophrenia (Henderson et 
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al., 2012; Ragland et al., 2012). Consistent with CINTRAC’s mission, future work can establish a set of 
specific task parameters (e.g. how long a participant has to respond, stimulus timing, inter-stimulus and 
inter-trial intervals) designed to achieve optimal sensitivity for detecting cognitive impairments 
experienced by a portion of BCS. For example, by adjusting the number of AY and BX trails in the DPX 
task, it may be possible to further tease apartment deficits in selective attention, response control, and 
working memory which would further improve the ability to predict which individual BCS were most 
likely to experience CRCI. With the DPX, by modifying the proportion of AY and BX trials, it is further 
possible to bias individuals toward engaging in a specific cognitive strategy, namely, proactive versus 
reactive cognitive strategies (Gonthier et al., 2016). Other approaches have assessed the effects of altering 
the period between successive decisions in BCS. Using a modified Delayed Match to Sample test with 
variable stimulus delays, Janelsins and colleagues (2018) were able to show that BCS show declines in 
visual and short-term working-memory ability from baseline to 6 months post-CT treatment. No such 
decline was found in healthy control participants (Janelsins et al., 2018). The inclusion of additional 
experimental paradigms may also prove beneficial. Experimental paradigms such as feature and 
conjunction-based visual search tasks are commonly used to assess age-related cognitive decline and may 
further help tease apart specific deficits in attention. The predictive utility of such paradigms may be 
further realized when combined with alternative statistical models that capture speed-accuracy tradeoffs 
(e.g. drift-diffusion modeling or linear ballistic accumulation models; see Monge et al., 2017; Porter et al., 
2010). In summation, the combination of sensitive experimental paradigms and robust statistical 
modeling procedures will open up new avenues for assessing CRCI and can help reduce the level of 





Previous research highlights that cognitive difficulties, which negatively impact an individual’s 
quality of life and interfere with skills of daily living, can be subtle, yet have the potential to contribute to 
serious long-term impairment. Classification of individual BCS from healthy age-matched control 
participants was significantly improved by combining self-report measures, neuropsychological 
assessments, and experimental cognitive neuroscience-inspired paradigms. Overall, the current results 
suggest that the interaction between self-reported measures of fatigue, stress, and distractibility with 
cognitive assessments tapping both general and specific aspects cognition in the domains of attention, 
executive function, and memory, are best able to distinguish BCS experiencing CRCI from healthy age-
matched participants who may also present with specific profiles of cognitive impairment. 
Given the complexity of CRCI, machine learning or other multivariate analytical approaches may 
be preferable to more traditional statistical methods that rely on null-hypothesis testing. The methods 
applied here are flexible and can be scaled to include additional factors that contribute to CRCI. Future 
work will strive to improve the accuracy and reliability of the current models by incorporating biological 
markers including inflammatory cytokines, and metrics that capture the reorganization of structural and 
functional brain networks that are associated with specific cognitive deficits. Neuroimaging research 
involving both human and animal models (Fardell, Vardy, & Johnston, 2013; Rendeiro et al., 2016; Root, 
Andreotti, Tsu, Ellmore, & Ahles, 2016) has identified widespread changes in brain structure (volumetric 
reductions in white and grey matter) and function after treatment with chemotherapy (Eisenberger, 
Inagaki, Rameson, Mashal, & Irwin, 2009; Shelli R. Kesler, Kent, & O’Hara, 2011).  
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Many of these observations occur in the absence of any measured cognitive impairment. Whether 
or not this observation is purely an artifact in the choice of neuropsychological assessments remains to be 
determined. 
Critically, all BCS were able to complete the comprehensive 3-hour battery of testing and 
performed quite well overall. Although preliminary, the present results highlight the utility of combining 
comprehensive cognitive paradigms that permit accurate decomposition of an individual’s performance, 
with a subset of traditional neuropsychological and self-report measures. Understanding the precise nature 
of cognitive impairment in BCS is a critical step toward developing targeted early-intervention efforts 
aimed at minimizing the negative impacts of cognitive decline on the quality of life of breast cancer 
survivors (Schagen et al., 2014). To be able to identify optimal treatment plans and assess effective 
rehabilitation strategies designed to limit or reduce levels of cognitive impairment experienced by an 
individual, clinicians and therapists require reliable estimates that pinpoint specific cognitive processes 
which may be compromised after an initial cancer diagnosis, throughout the term of treatment with 
chemotherapy, and over a greater period of time.  
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SUPPLEMENTAL FIGURES & TABLES 
Supplemental Figure 14. Correlation structure for self-report measures.  
Heatmap displays the correlation of features on a scale from -1 to 1. Cooler colors indicate more negative 




Supplemental Figure 15. Correlation structure for neuropsychological assessments.  
Heatmap displays the correlation of features on a scale from -1 to 1. Cooler colors indicate more negative 





Supplemental Figure 16. Correlation structure for experimental cognitive neuroscience metrics. 
Heatmap displays the correlation of features on a scale of -1 to 1. Cooler colors indicate more negative 






Supplemental Figure 17. Distribution on self-report measures. 
Error bars indicate the smallest and largest values within 1.5 times the interquartile range, below and 
above the 25th and 75th percentiles respectively. Horizontal lines indicate the median (50th percentile) for 












Supplemental Figure 18. Distribution of performance on neuropsychological assessments.  
Error bars indicate the smallest and largest values within 1.5 times the interquartile range, below and 
above the 25th and 75th percentiles respectively. Horizontal lines indicate the median (50th percentile) for 
each respective group. Individual participant values are represented by black dots. Group (Left: HC, blue; 
Right: BCS, red) differences and a degree of variability are present on the d2 Test of Attention and HVLT 
assessments. For most other metrics, there appears to be little variation except for assessments where 





Supplemental Figure 19. Distribution of performance on experimental cognitive neuroscience metrics. 
Error bars indicate the smallest and largest values within 1.5 times the interquartile range, below and 
above the 25th and 75th percentiles respectively. Horizontal lines indicate the median (50th percentile) for 
each respective group (Left: HC, blue; Right: BCS, red). Individual participant values are represented by 
black dots. Overall, there appears to be a good deal of variability across metrics for the DPX and RISE 
tasks. Although the CCF task was ranked the most difficult task from the battery of experimental 









































 total item score on self-reported stress levels 






composite score of self-reported sleep quality 
scale (0-3) 
psq.overall 
 total item score of overall sleep quality (0-21); 
measure accounts for several factors including 






General measure of self-reported energy level 
mfs.physical 
measure of self-reported fatigue in physical 
domain 
mfs.emotional measure of self-reported emotional fatigue 






composite score of self-reported forgetfulness 
(0: never; 1: very rarely; 2: occasionally; 3: 
quite often; 4: very often) 
cfq.distractability 
composite score of self-reported distractibility 
(0: never; 1: very rarely; 2: occasionally; 3: 
quite often; 4: very often) 
cfq.inhibition 
composite score of self-reported deficits in 
inhibition (0: never; 1: very rarely; 2: 





composite score; perceived physical health 
status (1: not at all; 2: a little; 3: moderately; 4: 
quite a bit; 5: extremely) 
sf.fatigue 
composite score; perceived energy level (1: not 





composite score; perceived emotional health 
status (1: not at all; 2: a little; 3: moderately; 4: 
quite a bit; 5: extremely) 
sf.social 
composite score; perceived level of social 
engagement (1: not at all; 2: a little; 3: 
moderately; 4: quite a bit; 5: extremely) 
sf.pain 
composite score; perceived physical pain level 
(1: not at all; 2: a little; 3: moderately; 4: quite a 







composite score; perceived difficulty of task and 
performance (1: not at all; 2: a little; 3: 
moderately; 4: quite a bit; 5: extremely) 
dq.rise 
composite score; perceived difficulty of task and 
performance (1: not at all; 2: a little; 3: 
moderately; 4: quite a bit; 5: extremely) 
dq.ccf 
composite score; perceived difficulty of task and 
performance (1: not at all; 2: a little; 3: 
moderately; 4: quite a bit; 5: extremely) 
dq.cogneuro 
composite score; perceived difficulty of task and 
performance (1: not at all; 2: a little; 3: 










total items correct; general measure of reasoning 
ability IQ 
d2.tn 
d2 Test of 
Attention (d2) 
total number of items crossed-out; measures 














accuracy, total number of items crossed-out 
minus errors; measures selective attention 
d2.errors 
total number of commission and omission 
errors; measures attention 
d2.cp 
total number of items crossed-out minus 











total number of words recalled during a series of 
three learning trials; measure memory encoding 
and free recall 
hvlt.delayed 
total number of words remembered after a 20-
minute delay; measure recollection memory 
hvlt.rentention 
total number of words correctly remembered; 
measures memory retention 
hvlt.discrimination  
total number of words correctly remembered 









overall performance; measures ability to 
override prepotent response to conflicting 
information in order to read color of ink a word 
is printed in 
dkefs.cw.inhibit.err 
total items incorrect; measures ability to 
override prepotent response to conflicting 
information in order to read color of ink a word 
is printed in 
dkefs.cw.switch 
overall performance; measures ability to flexibly 
shift between changing stimulus demands in 
order to read either the ink a word is printed in, 
or the word itself 
dkefs.cw.switch.err 
total items incorrect; measures ability to flexibly 
shift between changing stimulus demands in 
order to read either the ink a word is printed in, 
or the word itself 
dkefs.cw.time 
total to completion; measures speed as the time 
it takes to read a series of items 
dkefs.trails.scan 
overall performance; measures ability to visually 
identify and cross-out the number 3 situated on a 
page amongst many numbers ranging from 1-9 
dkefs.trails.scan.err total errors; measures visual processing deficits 
dkefs.trails.switch 
total items correct; measures ability to flexibly 
shift between changing stimulus demands to 
connects dots containing numbers and letters in 
alternating sequential order 
dkefs.trails.switch. 
seq.err 
number of sequential errors made; measures 
ability to maintain the correct order of items 




number of set loss errors made; measures ability 
to maintain an item set while flexibly shifting to 
changing stimulus demands (e.g. distractibility) 
dkefs.trails.time 
total to completion; measures speed as the time 






difference in mean response time between 
switch and hold items; measures cost of task 










difference in mean response time between 
switch and hold items; measures cost of task 
switching in blocks with equal switch/hold 
probability 
ccf.MS.cost 
difference in mean response time between 
switch and hold items; measures cost of task 




accuracy; measures overall task switching 
ability during trials with a greater number of 
hold items 
ccf.EQ.acc 
accuracy; measures overall task switching 
ability when number of hold and switch trials 
are equal 
ccf.MS.acc 
accuracy; measures overall task switching 
ability during trials with a greater number of 
switch trials 
ccf.MH.meanRT 
mean response time; measures efficiency of 
responses to task switching demands during 
trials with greater proportion of hold trials 
ccf..EQ.meanRT 
mean response time; measures efficiency of 
responses to task switching demands during 
trials with equal proportion of switch and hold 
trials 
ccf.MS.meanRT 
mean response time; measures efficiency of 
responses to task switching demands during 





accuracy; measures ability to identify the target 
valid/invalid cue-probe stimulus pairing 
dpx.targAY.acc 
accuracy; measures ability to inhibit prepotent 
response to valid/invalid cue-probe stimulus 
pairing 
dpx.targBX.acc 
accuracy; measures ability to inhibit response to 
invalid/valid cue-probe stimulus pairing 
dpx.targBY.acc 
accuracy; measures ability to identify 
invalid/invalid cue-probe stimulus pairing 
dpx.targAX.meanrt 
response time; measures ability to identify target 
sequence 
dpx.targAY.meanrt 
response time; measures ability to inhibit 
prepotent response to valid/invalid cue-probe 
stimulus pairing 
dpx.targBX.meanrt 
response time; measures ability to inhibit 
response to invalid/valid cue-probe stimulus 
pairing 
dpx.targBY.meanrt 
response time; measures ability to inhibit 





accuracy, total number of items correctly 






accuracy, total number of item-pairs correctly 
processed; measures encoding memory for 
relational item pairs 
rise.Iret.acc 
accuracy, total number of items correctly 
remembered; measures item recognition 
memory  
rise.Rrett.acc 
accuracy, total number of item-pairs correctly 
remembered; measures relational memory  
rise.Ienc.rt 
mean response time; measures processing speed 
and encoding memory of items 
rise.Renc.rt 
mean response time; measures processing speed 
and encoding memory of relational item-pairs 
rise.Iret.rt 
mean response time; measures processing speed 
and item recognition memory 
rise.Rret.rt 
mean response time; measures processing speed 
and relational memory 
 
Supplemental Table 1. Features included in the current analysis.  
Labels and descriptions for all features from demographic, self-report, IQ, neuropsychological and 





 mean std. dev. median range skew   
Features HC BCS HC BCS HC BCS HC BCS HC BCS t p 
age 49.65 53.05 13.82 9.89 50 53.5 72 33 0.2 -0.05 -0.90 0.38 
weight 160 171.75 35.52 52.8 146.5 163 230 180 0.5 0.61 -0.83 0.42 
bds.total 4.45 11.3 5.39 8.74 3 10 21 32 1.64 0.68 -2.98 0.01 
pss.total 11.2 16.75 5.22 9.62 11 16.5 21 32 0.14 0.24 -2.27 0.03 
psq.quality 1.95 2.15 0.94 1.04 2 3 3 3 -0.26 -0.55 -0.64 0.53 
psq.overall 7.95 10.7 5.13 5.01 7 11.5 17 19 0.54 0.03 -1.71 0.10 
mfs.physical 2.05 4.5 2.93 4.82 1 2 11 17 2.01 1.07 -1.94 0.06 
mfs.emotional 3.2 6.55 3.62 5.96 2.5 5 14 18 1.49 0.45 -2.15 0.04 
mfs.mental 3.5 7.4 3.65 6.15 2 6 12 18 0.92 0.39 -2.44 0.02 
mfs.vigor 14.5 12.15 4.01 7.05 15 14 21 22 -0.76 -0.11 1.30 0.21 
cfq.forgetfulness 11 14.7 4.28 5.3 10.5 14.5 20 19 0.56 -0.13 -2.43 0.02 
cfq.distractability 9.1 13.35 4.51 5.53 8 13.5 18 20 0.61 0.1 -2.67 0.01 
cfq.inhibition 5.8 7.7 3.29 3.77 5.5 7 13 12 0.45 0.37 -1.70 0.10 
sf.general 72.5 71.31 20.29 19.96 75 75 100 65 -0.46 -0.46 0.19 0.85 
sf.physical 85.91 73.18 21.67 27.27 95.45 86.36 100 81.82 -1.68 -0.99 1.63 0.11 
sf.fatigue 57.5 56.5 22.8 29.2 67.5 55 80 85 -0.83 -0.11 0.12 0.90 
sf.emotional 80.8 73 12.56 22.73 84 84 96 76 -1.44 -0.77 1.34 0.19 
sf.social 84.38 78.75 24.29 24.4 100 81.25 100 75 -1.46 -0.73 0.73 0.47 
sf.pain 78.12 71.75 18.88 22.42 85 67.5 100 77.5 -0.42 -0.5 0.97 0.34 
dq.dpx 9.7 11.3 4.85 6.4 9 11.5 19 26 0.23 0.2 -0.89 0.38 
dq.rise 7.55 9.9 4.75 6.72 7 9.5 18 22 0.73 0.07 -1.27 0.21 
dq.ccf 16.9 15.15 4.89 7.2 16.5 15 26 27 0.18 -0.08 0.90 0.38 
dq.cogneuro 11.15 12.1 4.39 6.18 13 12.5 16 24 -0.97 -0.05 -0.56 0.58 
wais.vocab 15.53 12.47 6.79 3.94 14 13 41 18 2.65 -0.88 1.70 0.10 
wais.matrix 46.37 47.11 12.98 7.06 50 48 57 21 -1.86 -0.17 -0.22 0.83 
d2.tn 495 477.55 91.75 77.1 480.5 477.5 650 309 0.28 -0.33 0.65 0.52 
d2.tn-e 468.9 449.65 85.44 68.2 470 456.5 615 252 0.29 -0.37 0.79 0.44 
d2.errors 26.1 28.05 21.55 25.1 23 17.5 80 75 1.25 0.63 -0.26 0.79 
d2.cp 200.7 177.8 42.15 27.0 197.5 178 286 88 0.2 -0.23 2.05 0.05 
hvlt.recall 30.7 28.65 3.2 4.28 31.5 28 36 13 -0.26 0.28 1.73 0.10 
hvlt.delayed 10.85 10.15 1.46 1.6 11 10 12 5 -1.68 -0.23 1.45 0.16 
hvlt.rentention 97.15 96 8.82 10.5 100 100 110 45 -1.77 0.17 0.38 0.71 
hvlt.discrim 12.4 11.4 2.28 0.94 12 12 22 3 3.7 -1.17 1.81 0.08 
dkefs.cw.Inhibit 50.95 49.75 15.35 6.89 45 49.5 80 27 0.49 0.59 0.31 0.76 
dkefs.cw.switch 56.16 58 12.27 9.53 56 55 83 42 0.05 1.16 -0.52 0.61 
dkefs.cw. 
   inhibit.err 




   switch.err 
0.89 1.05 1.2 1.32 1 1 5 5 2.03 1.36 -0.39 0.70 
dkefs.cw.time 395.2 380.4 110.7 81.1 368 360 760 341 1.82 0.88 0.48 0.64 
dkefs.trails.scan 21.68 23.55 7.95 7.16 19 22.5 41 27 1.12 1.03 -0.77 0.44 
dkefs.trails. 
switch 
66.32 70.05 18 27.1 64 61.5 112 121 0.47 1.52 -0.51 0.61 
dkefs.trails. 
   scan.err 
0.16 0.2 0.37 0.52 0 0 1 2 1.73 2.35 -0.29 0.77 
dkefs.trails. 
switch.seq.err 
0.32 0.15 0.58 0.49 0 0 2 2 1.5 2.94 0.96 0.34 
dkefs.trails. 
switch.setloss.err 
0 0.35 0 0.59 0 0 0 2 0 1.3 -2.67 0.02 
dkefs.trails.time 514.4 462.9 233.6 96.5 464 462.5 1447 495 3.32 2.52 0.89 0.38 
ccf.MH.cost 154.7 202.66 148.1 115.4 142.3 181.9 491.6 503.1 0.43 1.14 -1.13 0.27 
ccf.EQ.cost 116.4 150.1 121.14 129.92 117.28 131.48 466.6 450.3 0.68 0.66 -0.84 0.41 
ccf.MS.cost 96.4 82.2 91.07 104.81 102.24 63.06 299.4 408.6 -0.01 0.25 0.45 0.65 
ccf.MH.acc 87.95 92.43 8.62 4.87 90.62 91.67 97.92 16.67 -1.04 0 -2.01 0.05 
ccf.EQ.acc 84.99 88.71 12.44 7.96 88.54 91.67 100 29.17 -0.88 -0.46 -1.12 0.27 
ccf.MS.acc 85.96 90.35 13.62 6.45 87.5 91.67 100 27.08 -1.5 -0.87 -1.30 0.21 
ccf.MH.meanRT 870.5 848.32 101.25 84.31 874.82 852.29 1125.7 412.2 0.31 1.46 0.75 0.46 
ccf.EQ.meanRT 917.4 916.08 104.6 144.74 907.87 891.97 1167.3 704.5 0.61 1.85 0.03 0.98 
ccf.MS.meanRT 926.6 948.39 127.8 163.03 917.42 943.81 1336.8 762.3 1.37 2 -0.46 0.65 
dpx.targAX.acc 0.94 0.95 0.05 0.03 0.96 0.95 1 0.12 -1.26 -0.58 -0.46 0.65 
dpx.targAY.acc 0.72 0.69 0.26 0.22 0.78 0.72 1 0.95 -0.75 -1.61 0.34 0.73 
dpx.targBX.acc 0.9 0.87 0.11 0.13 0.95 0.9 1 0.45 -0.77 -1.13 0.77 0.45 
dpx.targBY.acc 0.9 0.95 0.14 0.09 1 1 1 0.38 -1.24 -2.07 -1.35 0.19 
dpx.targAX.rt 0.42 0.43 0.05 0.05 0.42 0.42 0.52 0.18 0.29 0.02 -0.69 0.49 
dpx.targAY.rt 0.52 0.57 0.09 0.06 0.53 0.57 0.66 0.27 -0.59 -0.74 -1.98 0.06 
dpx.targBX.rt 0.39 0.44 0.06 0.08 0.37 0.44 0.51 0.3 0.41 -0.29 -2.04 0.05 
dpx.targBY.rt 0.42 0.44 0.09 0.09 0.44 0.47 0.56 0.36 -0.07 -0.2 -0.71 0.49 
rise.Ienc.acc 0.87 0.83 0.06 0.06 0.86 0.82 1 0.22 -0.47 0.76 1.77 0.09 
rise.Renc.acc 0.76 0.77 0.1 0.11 0.72 0.78 0.89 0.39 0.06 0.3 -0.12 0.91 
rise.Iret.acc 0.92 0.92 0.04 0.04 0.92 0.92 0.99 0.18 -0.87 -0.47 0.26 0.80 
rise.Rret.acc 0.84 0.8 0.12 0.12 0.85 0.78 1 0.44 -0.19 -0.08 0.95 0.35 
rise.Ienc.rt 0.97 1.09 0.16 0.17 0.95 1.08 1.27 0.69 0.11 -0.16 -2.23 0.03 
rise.Renc.rt 1.73 1.99 0.32 0.34 1.77 2.01 2.51 1.56 0.46 -0.91 -2.53 0.07 
rise.Iret.rt 1.45 1.53 0.27 0.4 1.46 1.54 2.08 1.5 0.33 0.34 -0.71 0.49 
rise.Rret.rt 2.09 2.43 0.45 0.66 1.99 2.21 3.22 2.07 0.83 0.57 -1.93 0.06 
Supplemental Table 2. Summary statistics and results of independent two-sample t-tests for all 
features. 
Group-level summary statistics are provided for all features (before EDA). The last two columns contain 
uncorrected p-values for an independent two-sample t-test. Features with uncorrected p-values lower than 
the stated alpha level of .05 are highlighted in pink. Highlighted measures include response time 
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differences between groups on item encoding from the RISE task, and during the target BX condition 
which is an index of working memory from the DPX task. Additional measures that indicate potential 
response time differences are the concentration performance metric from the d2 Test of Attention and set-
loss errors from the DKEF’s Trail-Making task. Several self-report metrics exhibited group mean 
differences including fatigue, stress, and depression, as well as on items assessing self-reported cognitive 
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